IRB-32275  1 of 59 21 August  2018;  Amendment  8 TITLE :  A pilot study of Dabrafenib  and Trametinib  for patients with BRAF -mutated  
ameloblastoma  
[STUDY_ID_REMOVED]  
Coordinating Center  
Stanford Cancer Institute  
875 Blake Wilbur Drive , Stanford, CA 94305  
Protocol Director  
A Dimitrios  Colevas,  MD, Professor in Medicine  
Stanfo rd University Medical Center  
Blake Wilbur Drive, Stanford, CA 94305 -5826  
 
 
colevas@stanford.edu  
Co-Investigators  
Robert West  
Professor in Pathology Pathology  
Stanford, Cali fornia 94305 -5324  
 
 Jonathan Pollack  
Professor in Pathology  
269 Campus Drive , Stanford, California 
94305 -5176  
 
 
Davud Sirjani  
Clinical Assistant Professor  
  
Biostatistician  
Alex McMillan  
Sr Res Scientist -Basic Ls  
HRP (Redwood) Building  
Stanford, California  94305  
 
 Study Coordinator  
Elizabeth Winters  
 
 
Protocol Amendment 8:  21 August  2018  
IRB-32275  2 of 59 21 August  2018;  Amendment  8 TAB LE OF CONTENTS  
 
PROTOCOL SYNOPSIS  ................................ ................................ ................................ ...................  4 
SCHEMA  ................................ ................................ ................................ ................................ .............  5 
LIST OF ABBREVIATIONS AND DEFINITION OF TERMS  ................................ ....................  6 
1.0 OBJECTIVES  ................................ ................................ ................................ ............................  7 
1.1 Primary Objectives  ................................ ................................ ................................ ................................ ..... 7 
1.2 Secondary Objectives  ................................ ................................ ................................ ................................  7 
2.0 BACKGROUND  ................................ ................................ ................................ ........................  7 
2.1 Study Disease  ................................ ................................ ................................ ................................ ...............  7 
2.2 Study Agents/Device/Procedur e ................................ ................................ ................................ ..........  9 
2.3 Rationale  ................................ ................................ ................................ ................................ ......................  10 
2.4 Study Design  ................................ ................................ ................................ ................................ ...............  11 
2.5 Correlative Studies Background  ................................ ................................ ................................ .........  11 
3.0 PARTICIPANT SELECTION AND ENROLLMENT PROCEDURES  ............................  12 
3.1 Participant Eligibility Checklist  ................................ ................................ ................................ ...........  12 
3.2 Informed Consent Process  ................................ ................................ ................................ .....................  18 
3.3 Study Timeline  ................................ ................................ ................................ ................................ ...........  18 
4.0 TREATMENT PLAN  ................................ ................................ ................................ ..............  18 
4.1 General Concomita nt Medication and Supportive Care Guidelines  ................................ ....... 19 
4.1.1  Permitted Medications and Non -Drug Therapies  ................................ ................................ ................  19 
4.1.2  Prohibited Medications and Non -Drug Therapies  ................................ ................................ ...............  20 
4.1.3  Medications to be used with Caution  ................................ ................................ ................................ .........  21 
4.2 Criteria for Removal from Study  ................................ ................................ ................................ .........  22 
5.0 STUDY AGENT INFORMATION  ................................ ................................ ........................  22 
5.1 Study  Agents:  ................................ ................................ ................................ ................................ ..............  22 
5.2 Availability  ................................ ................................ ................................ ................................ ..................  23 
5.3 Agent Ordering  ................................ ................................ ................................ ................................ ..........  23 
5.4 Agent Accountability  ................................ ................................ ................................ ...............................  23 
6.0 DOSE MODIFICATIONS  ................................ ................................ ................................ ...... 23 
6.1 Dose Modification for General Toxicities  ................................ ................................ .........................  23 
6.2 Dose Reductions for AEs of interest in patients taking dabrafenib and   trametinib  ....... 24 
6.2.1 Plantar -Palmar Erythrodysesthesia  ................................ ................................ ................................ ...........  24 
6.2.2  Pancreatitis  ................................ ................................ ................................ ................................ ...........................  25 
6.2.3  Uveitis and ocular events  ................................ ................................ ................................ ................................  25 
6.2.4  Hyperglycemia  ................................ ................................ ................................ ................................ ....................  27 
6.2.5  Pyrexia  ................................ ................................ ................................ ................................ ................................ .... 27 
6.2.6  Malignancies  ................................ ................................ ................................ ................................ ........................  29 
6.2.7  New Primary Melanoma  ................................ ................................ ................................ ................................ . 29 
6.2.8  Non -Cutaneous Malignancies  ................................ ................................ ................................ .......................  29 
6.2.9  Renal Insufficiency  ................................ ................................ ................................ ................................ ............  29 
6.2.10  Gudielines for Prolonges QTc ................................ ................................ ................................ ........................  31 
6.2.11  Guidelines for Pneumonitis  ................................ ................................ ................................ ...........................  32 
6.2.12  Guidelines for Cardiomyopathy  ................................ ................................ ................................ ...................  32 
6.2.13  Treatment of Study Treatment Overdose  ................................ ................................ ................................  34 
7 ADVERSE EVENTS AND REPORTING PROCEDURES  ................................ ................  34 
7.1 Potential Adverse Events  ................................ ................................ ................................ .......................  34 
7.1.1  Dabrafeni b potential adverse effects  ................................ ................................ ................................ .........  34 
7.1.2  Trametinib potential adverse effects  ................................ ................................ ................................ .........  38 
7.2 Adverse Event Reporting  ................................ ................................ ................................ .......................  42 
IRB-32275  3 of 59 21 August  2018;  Amendment  8 8 CORRELATIVE/ SPECIAL STUDIES  ................................ ................................ ................  44 
8.1 Laboratory Correlative Studies  ................................ ................................ ................................ ...........  45 
8.1.1  Collection  of Specimen(s)  ................................ ................................ ................................ ...............................  45 
8.1.2  Handling of Specimens(s)  ................................ ................................ ................................ ...............................  45 
8.1.3  Shipping of Specimen(s)  ................................ ................................ ................................ ................................ . 46 
8.1.4  Site(s) Performing Correlative Study  ................................ ................................ ................................ ........  46 
8.1.5 Coding of specimens for privacy protection  ................................ ................................ ...........................  46 
9 STUDY CALENDAR  ................................ ................................ ................................ ...............  47 
10 MEASUREMENTS  ................................ ................................ ................................ ..................  49 
10.1  Primary and Secondary Outcome measures  ................................ ................................ ...................  50 
10.1.1  Measurement Definition  ................................ ................................ ................................ ................................ . 50 
10.1.2  Measurement Methods  ................................ ................................ ................................ ................................ .... 50 
10.1.3  Measurement Time Point s ................................ ................................ ................................ .............................  50 
10.2  Secondary Outcome  ................................ ................................ ................................ ................................ . 50 
10.2.1  Tumor necrosis  ................................ ................................ ................................ ................................ ...................  50 
10.2.2  Measurement Definition  ................................ ................................ ................................ ................................ . 50 
10.2.3  Measurement Methods  ................................ ................................ ................................ ................................ .... 50 
10.2.4  Measurement Time Points  ................................ ................................ ................................ .............................  51 
10.2.5  Response Review  ................................ ................................ ................................ ................................ ...............  51 
10.3  Secondary Outcome – Proliferation index  ................................ ................................ .......................  51 
10.3.1  Measurement Definition  ................................ ................................ ................................ ................................ . 51 
10.3.2  Measurement Methods  ................................ ................................ ................................ ................................ .... 51 
10.3.3  Measurement Time Points  ................................ ................................ ................................ .............................  51 
10.3.4  Response Review  ................................ ................................ ................................ ................................ ...............  51 
10.4  Secondary Outcome – Phosphorylation of MEK/ERK  ................................ ................................ .. 51 
10.4.1  Measurement Definition  ................................ ................................ ................................ ................................ . 52 
10.4.2  Measurement Methods  ................................ ................................ ................................ ................................ .... 52 
10.4.3  Measurement Time Points  ................................ ................................ ................................ .............................  52 
10.4.4  Response Review  ................................ ................................ ................................ ................................ ...............  52 
11 REGULATORY CONSIDERATIONS  ................................ ................................ ..................  52 
11.1  Institutional Review of Protocol  ................................ ................................ ................................ .........  52 
11.2  Data and Safety Monitoring Plan:  ................................ ................................ ................................ ....... 52 
11.3  Data Management Plan  ................................ ................................ ................................ ...........................  53 
11.3.1  Data Collection  ................................ ................................ ................................ ................................ ....................  53 
11.3.2  Data Submission responsibility  ................................ ................................ ................................ ...................  53 
11.3.3  Multicenter Guidelines  ................................ ................................ ................................ ................................ .... 53 
12 STATISTICAL CONSIDERATIONS  ................................ ................................ ...................  53 
12.1  Statistical Design and primary analysis  ................................ ................................ ...........................  53 
12.2  Secondary Analysis  ................................ ................................ ................................ ................................ .. 54 
12.3  Sample Size  ................................ ................................ ................................ ................................ .................  54 
12.4  Accrual estimates  ................................ ................................ ................................ ................................ ..... 54 
12.5 Feasibility and safety assessment ................................ ................................ ................................ ....... 54 
13 REFERENCES  ................................ ................................ ................................ .........................  55 
Appendix A :  Medication guide for patien ts ................................ ................................ ..................  58 
Appendix B :  Stanford Cancer Institute Serious Adverse Event Reporting  ...............................  58 
Appendix C:  ECOG Performance Status  ................................ ................................ ......................  59 
Appendix D:  Cockcroft -Gault Formula ................................ ................................ .........................  60 
Appendix E:  Ophthalmic exam source sheet  ................................ ................................ ................  60 
IRB-32275  4 of 59 21 August  2018;  Amendment  8 PROTOCOL SYNOPSIS  
In the table below summarize the  basic aspects of this research .  This is to be used as a quick 
reference guide .   
 
TITLE  A pilot study of Dabrafenib and Trametinib for 
patients w ith BRAF -mutated  ameloblastoma  
STUDY PHASE  Pilot  
INDICATION  Ameloblastoma  
INVESTIGATIONAL PRODUCT OR 
PROC EDURE  Dabrafenib  and trametinib  
PRIMARY OBJECTIVE(S)  Tumor response rate  
SECONDARY OBJECTIVE(S)  Feasibility, safety, pathological response, 
evidence of molecular pathway inhibition  
TREATMENT SUMMARY  Dabrafenib 150  mg po q 12  hours plus 
trametinib 2  mg once daily.  
SAMPLE SIZE  17 evaluable patients  
STATISTICAL CONSIDERATIONS  Simon Optimal 2 stage design  
 
IRB application number:  IRB -32275  
By determination of the Principal  Investigator and the IRB, this study is considered IND -Exempt.  
 
IRB-32275  5 of 59 21 August  2018;  Amendment  8 SCHEMA  
 
  
 
  
 
                        
   
                                             SD, PR, or CR
                    Progression or intolerable AEs
 
                                           
                        YES 
 No
                                         
        
 
                                                                 
                                                                   
                                                                                
                                                                     
                                                                                                               
                                                                                                                 
 
 Pathologically -documented ameloblastoma with BRAF -V600E or other known 
Dabrafenib -sensitive BRA F mutation in tumor by any CLIA -certified lab  
Confirmation of eligibility and documentation of informed consent  
Baseline  biopsy, imaging, staging and clinical assessment by  
both ENT  / oral surgeon and medical  oncologist.  
Dabrafenib  150 mg PO q12hr plus 
Trametinib  2 mg daily PO   x 6 weeks  Response and AE assessment q3  weeks  x 2  
(see below for later assessment intervals ) 
Assessment at 6  weeks:  
Surgically resectable?  Biopsy and evaluation of 
pathological endpoints  
Resection and evaluation of pathological endpoints.  
No additional dabrafenib or trametinib  Biopsy and evaluation of 
pathological endpoints  Off-study  
Continue dabrafenib and trametinib, evaluate 
for DLT and response every 6  to 9 weeks 
with dose modifications per protocol  
SD, P R, or CR  without 
intolerable  AEs Progression or 
intolerable  AEs 
Off-study  
IRB-32275  6 of 59 21 August  2018;  Amendment  8  
LIST OF ABBREV IATIONS AND DEFINITION OF TERMS  
 
ADL  Activities of daily living  
AE Adverse event  
BID Twice daily  
BSA  Body surface area  
CBC  Complete blood count  
CI Confidence interval  
CRF  Case report/Record form  
CR Complete response  
CTCAE  Common Terminology Criter ia for Adverse Events  
DLT  Dose -limiting  toxicity  
DSMB  Data Safety Monitoring Board  
ECG  Electrocardiogram  
GI Gastrointestinal  
Hgb Hemoglobin  
HTN  Hypertension  
IRB Institutional Review Board  
IV Intravenous  
LLN  Lower limit of normal  
OS Overall survi val  
PLT Platelet  
PD Progressive diseased  
PFS Progression free survival  
PR Partial response  
QD Once daily  
RECIST  Response evaluation criteria in solid tumors  
RR Response rate  
SAE  Serious adverse event  
SD Stable disease  
TTP Time to progression  
ULN Upper limit of normal  
UNK  Unknown  
WBC  White blood cell  
 
IRB-32275  7 of 59 21 August  2018;  Amendment  8 1.0 OBJECTIVE S 
1.1 Primary Objectives  
To observe the response rate of ameloblastoma to dabrafenib  plus trametinib  at 6 week s. 
1.2 Secondary Objectives  
Secondary endpoints will include feasibility and safety  in this patient population .  
Additionally, response will be assessed pathologically .  Two main histologic assays for 
treatment response will be used :  tumor necrosis and phosphorylated -MEK ;  
phosphorylated -ERK ;  and Ki -67 levels as measured by immunohisto chemistry .   
2.0 BACKGROUND  
2.1 Study Disease  
Ameloblastoma is a rare, benign, slow -growing but locally -invasive neoplasm of 
odontogenic origin involving the mandible (80%) and maxilla with a high recurrence rate 
attributed to conservative treatment .  The neoplasm  was first described by Cusack in 1827 . 
{Cusack, 1827 }  Etymologically, the name derives from the old French word "amel" which 
means enamel and the Greek word "blastos" meaning germ or bud .  Over time, this tumor 
has been referred to by many different name s includ ing “cystosarcoma,” 
“adamantine  epithelioma,” “adamantinoma,”  and finally “ameloblastoma.”  {Ivy, 1930 ;  
Malassez, 1885 ;  Wedl, 1870 ;  Brazis, 1995 ]  
Ameloblastoma shows variable geographic prevalence, being the most common b enign 
odontoge nic tumor in China  {Lu, 1998 ;  Wu, 198 5} and A frica {Anand, 1967 ;  
Mosadomi , 1975 ;  Barnes, 2005 }, while it is the second most common  in the United Sta tes 
and Canada {Daley, 1994 ;  Regezi, 1978 } (odontoma being most common) .  Racial bias 
has also been observed, with  African Americans at an overall five -fold increased risk of 
disease versus Caucasians . {Regezi, 1978 }  Global incidence has been estimated at 0.5 
cases per million person years, with most cases diagnosed in the age range of 30 to 60 
years . {Larsson, 1978 }  
Up to 80% of ameloblastoma cases occur in the mandible, with a particular predilection for 
the posterior mandibular region . {Reichart, 1995 }  Rare cases have been reported as 
primary to the sinonasal cavities . {Schafer, 1998 }  Often ameloblastoma can be associated 
with unerupted third molar teeth  {Stanley, 1965 ;  Gerzenshtein, 2006 ;  Becelli, 2002 } 
particularly in the unicystic type .  Desmoplastic ameloblastomas often occur in the anterior 
or premolar regions of the mandible or maxilla .  Ameloblastic carc inomas also favor the 
mandible (~2/3) over the maxilla . {Slootweg, 1984 }  Maxillary ameloblastomas also 
mostly occur in the posterior molar region.  
Histopathologically, ameloblastoma resembles normal odontogenic/enamel epithelium and 
ectomesenchyme .  Odont ogenesis consists of chronographic and reciprocal interactions 
between the ectomesenchymal cells, which are derived from the neural crest, and the oral 
cavity lining epithelium . {Chai, 2000 }  The exact origin of ameloblastic epithelium has 
been hypothesize d to arise from :  (1) cells from the rests  of enamel organ, ( 2) cells of the 
sheet of Hertwig’s or epithelial cell rest of Malassez, (3) epithelial boundary of an 
odontogenic cyst, particularly a dentigerous cyst, (4) basal cells of the oral mucosa, and ( 5) 
IRB-32275  8 of 59 21 August  2018;  Amendment  8 heterotrophic epithelial from other parts of the body, perhaps pituitary . {Ritchie, 1990 ;  
Bhasker, 198 1}  
Until recently, little was known about the molecular aberrations driving ameloblastoma, 
due to the tumor’s rarity and the fact that technologies to  query the tumor genome do not 
work as efficiently in formalin -fixed paraffin -embedded tissue .  However, in 2014 , three 
separate reports , including one form our group at Stanford, profiling ameloblastoma via 
DNA sequencing were published, all showing the v ast majority of tumors to contain 
somatic mutations impacting the mitogen -activated protein kinase (MAPK) signaling 
pathway (FGFR2 -> RAS -> BRAF) that controls cell proliferation . {Kurppa, 2014 ;  
Sweeney, 2014 ;  Brown, 2014 }  
In particular, all three studi es reported a high frequency of BRAF -V600E (valine to 
glutamic acid substitution at amino  acid 600) activating mutations at high allele frequencies 
in ameloblastomas .  In each of these reports, the BRAF -mutated neoplasms were almost 
exclusively located in the mandible .  Two of the three reports went on to characterize the 
sensitivity of BRAF -mutated ameloblastoma cells to vemurafenib, a V600E targeted small 
molecule inhibitor FDA -approved for metastatic melanoma .  Both studies showed that 
AM-1, a mandibular -derived ameloblastoma cell line harboring the BRAF -V600E 
mutation, was exquisitely sensitive to vemurafenib at concentrations similar to 
BRAF -V600E mutated melanoma and colorectal cancer cell lines .   
Surgery is the standard treatment for ameloblastomas .  Historically, the extent of resection 
has been controversial, comprising of two surgical options :  “conservative” vs.  “radical” .  
The former involves enucleation/curettage of the bony cavity, while the latter involves a 
radical operation with proper marg ins.  Advantages of enucleation include the fact that it is 
an outpatient procedure able to be performed by many different service providers (Oral 
Surgeons and ENT), since it requires no reconstruction .  Despite these facts, historical data 
on simple enucl eation demonstrate recurrence rates 60  to 90% and this treatment modality 
is currently believed to play no role in the management of multicystic ameloblastomas . 
The “radical” surgical option is the current standard of care for ameloblastoma, which 
includes  enbloc resection with 1  to 2cm bone margins  {Sham, 2009 ;  Carlson, 2006 ;  
Gardner, 1980 ;  Williams, 1993 ;  Gortzak, 2006 ;  Becelli, 2011 ;  Pandya, 1972 } and 
immediate bone reconstruction to help with speech and sw allowing . {Sham, 2009 ;  
Vayvada, 2006 ;  Tsai, 2006 ;  Urken, 1991 ;  Urken, 1998 }  
The bony margin is defined as the distance away from the radiographic margin predicted to 
be disease free and oncologically safe to perform osteotomies .  Data from 82 
amelobla stoma specimens showed microscopic tumor extension 2  to 8mm (mean of 
4.5mm) beyond the radiographic boundaries of the tumor . {Carlson, 2006 }  Hence, the 
recommended bone margins are1  to 1.5cm for unicystic and 1.5  to 2cm for 
solid/multicystic histological types providing increased cure rates . {Wenig, 2007 ;  Becelli, 
2002 ;  Carlson, 2006 ;  Zwahlen, 2002 ;  Ueno, 1989 ;  Vayvada, 2006 }  Ameloblastic 
carcinoma requires 2  to 3cm bone margins with an elective neck dissection . {Ndukwe, 
2010 }  Therefore surgery for ameloblastoma, when possible, tends to be radical and 
disfiguring.  
Systemic chemotherapy has been attempted a number of times, with numerous agents and 
combinations being employed (see Table  1) {Gall, 1975 ;  Eliasson, 1989 ;  Ramadas, 1990 ;  
IRB-32275  9 of 59 21 August  2018;  Amendment  8 Grunwald, 2001 ;  Campbell, 2003 ;  Amzerin, 2011 ;  Van Dam, 2010 }.  Anecdotal  reports 
have suggested that ameloblastoma may be sen sitive to platinum based agents { Amzerin, 
2011 } although  occasional reports highlight lengthy survival without chemotherapy . 
{Ciment, 2002 ;  Hasim, 2007 }  Chemotherapy may also have a role in improvement of 
clinical symptoms in non -surgical patients . {Ciment, 2002 }  Much like radiotherapy 
though, only with continuous reporting of empirical case -based data will the role of 
systemic chemotherapy b e evaluable in this rare entity.  
Table  1:  Anecdota l reports of Chemotherapy in Ameloblastoma  
Case  Regimen  Response  Reference  
1 Cyclophosphamide, Methotrexate, 
5-Fluorouracil  None  Gall, et al, 1975 
2 Vinblastine, Cisplatin, Bleomycin  PR Eliasson , et al, 1989  
3 Adriamycin, Cisplatin, 
Cyclophosphamide  PR Ramadas , et al, 1990 
4 1st line :  5-Fluorouracil and Cisplatin ;                                    
2nd line :  Paclitaxel -Carboplatin  PR Grünwald , et al, 2001 
5 Cyclophosphamide  None  Campbell , et al, 2003 
6 Doxorubicin and Cisplatin  PR Amzerin , et al, 2011   
7 Gemcitabine and Carboplatin  PR Van Dam , et al, 2010 
2.2 Study Agent s 
Dabrafenib is a kinase inhibitor indicated for the treatment of patients with unresectable o r 
metastatic melanoma with BRAF -V600E mu tation as detected by an FDA -approved test .  
Dabrafenib is an inhibitor of some mutated forms of BRAF kinase s with in vitro IC50 
values of 0.65, 0.5, and 1.84 nM for BRAF -V600E, BRAF -V600K, and BRAF -V600D 
enzymes, respectively .   It is manufactured in 50 a nd 75  mg capsules .   
According to the FDA approved package insert , the safety of dabrafenib has been evaluated 
in 586 patients with BRAF -mutant melanoma, including 181 patients  treated for at least 6 
months and 86 additional patients for 12 months .  The mo st commonly occurring adverse 
reactions in these patients treated with dabrafenib  were, in order of decreasing frequency 
hyperkeratosis, headache, pyrexia, arthralgia, papilloma, alopecia, and palmar -plantar 
erythrodysesthesia syndrome (PPES) .  The most f requent adverse reactions leading to dose 
reduction of dabrafenib  were pyrexia  (9%) ;  PPES  (3%) ;  chills  (3%) ;  fatigue  (2%) ;  and 
headache  (2%).  
Dabrafenib has been demonstrated to induce response rates of 52% with a duration median 
of 5.6 months, in pati ents with BRAF -mutant melanoma .  There are presently no safety or 
efficacy data for dabrafenib in patients with BRAF -mutant ameloblastoma .  Dabrafenib is 
not FDA approved for treatment  of patients with ameloblastoma, therefore conduct of this 
study will be  under either an IND or FDA authorized IND  exemption .  
Trametinib is a kinase inhibitor of MEK1 and MEK2 FDA -approved for use in pat ients 
with metastatic V600E mutated melanoma based upon  a randomized control trial  (RCT ) of 
trametinib  vs chemotherapy in wh ich PFS ( 4.8 vs 1.5 mo) and RR ( 22% vs 8%) were 
IRB-32275  10 of 59 21 August  2018;  Amendment  8 higher in patients treated with trametinib . {Flaherty, 2012}   In January  2014 , the 
combination of dabrafenib and trametinib was appr oved  for the treatment of patie nts with 
BRAF -V600E mutant melanoma .  This a pproval was based upon a RCT which 
demonstrated an improvement in survival in the combination ( 25.1 mo median OS 
) vs dabrafenib alone (18.7  mo median OS) with corresponding response rates of 
69 vs 53% respectively . {Long, 2015}   Treatment -related adverse events occurred in 181 
(87%) of 209 patients in the dabrafenib and trametinib group and 189 (90%) of 211 patients 
in the dabrafenib only group ;  the most common was fever (108  patients, 52%) in the 
dabrafenib and trametinib group, and hyperkeratosis (70 pa tients, 33%) in the dabrafenib 
only group .  Grade 3 or 4 adverse events occurred in 67 (32%) patients in the dabrafenib 
and trametinib gro up and 66  (31%) patients in the dabrafenib only group .  Another RCT 
compared the combination of dabrafenib and trameti nib vs vemurafenib, another  TKI 
active against V600E mutant melanoma . {Robert , 2015}  In that  trial, the combination 
demonstrated improved PFS (11.4 vs 7.3 months), with similar AE and drug 
discontinuance rates.  
Therefore, it appears that in melanoma with  BRAF -V600E muta tions, t he combination is 
active and provides clinic al ben efit.  More recently, thi s combination has also been shown 
to be active in other cancers with this BRAF mutation . {Williams, 2015 ;  Brastianos, 2016 ;  
Escandel l, 2015}  Most relevant  is a report of a dramatic  response in  a patient with 
BRAF -mutant ameloblastoma . {Kaye, 2015}  Earlier this year we treated an 
ameloblastoma patient who declined major surgical resection off -label with single agent 
dabrafenib .  After 2  months of treatment  the patient decided to have the resection .  We 
observed massive amounts of tumor necrosis in the specimen, a finding very atypical for 
untreated ameloblastoma  (report accepted for publication, Oral Surgery, Oral Medicine, 
Oral Pathology, Oral Radiology, 14 December  2015). 
2.3 Rationale  
Present accepted  standard of care treatment for  patients with ameloblastoma  is limited to 
surgical resection and reconstruction .  These operations for  patients with advanced disease 
are morbid and disfiguring .  There is no defin ed role  for radiation or chemotherapy 
treatment for ameloblastoma patients at any stage.  
Based on the recent discovery of potentially relevant BRAF mutations in ameloblastoma 
and preclinical data which suggest that BRAF -mutant ameloblastoma may respond to 
relevant mutant BRAF tyrosine kinase inhibition, we propose to ask in a pilot trial whether 
there is any evidence of anti - tumor activity against  ameloblastoma in patients with 
advanced disease .  Because of robust data with combined BRAF and MEK inhibition  in 
BRAF -mutant melanoma, we plan to use  dabrafenib and trametinib in combination .  
Novartis has agreed to supply bo th agents for this investigator -initiated study .  Because 
most patients with advanced disease have significant mandibular bone involvement but do 
not have metastatic disease, we are proposing a trial which will focus on this group of 
patients .  This allows us to ask in a preliminary way whether there is clinical, pathological, 
or microbiological  evidence of anti-cancer  activity of a relevant TKI, dabrafenib  in 
combination with a MEK inhibitor, trametinib,  in this situation .  The design  of the trial will 
facilitate collection of tissue at baseline and after 6  week s of treatment to allow for 
assessment of the pathological and microbiological end points, but will also not unduly 
delay attempts  at definitive surgical treatment  for appropriate pat ients.   
IRB-32275  11 of 59 21 August  2018;  Amendment  8 2.4 Study Design  
This will be a single -group, single -arm, 2-stage, open non -randomized  treatment study  
whose primary endpoint is tumor  response rate wi th feasibility, safety , pathological  and 
molecular biological secondary endpoints .   
2.5 Correlative Studies Background  
Activation of the Ras/Raf/MAPK signaling pathway begins with the binding of ligands to 
receptor -linked tyrosine kinases, such as epidermal g rowth factor receptor or fibroblast 
growth factor receptor .  This leads to phosphorylation of tyrosine residues on the receptor 
that then recruits adaptor proteins (eg , GRB2 and SOS) .  This protein complex allows SOS 
to switch to an activated state that in  turn leads to activation of Ras proteins by binding 
GTP .  This turns on the activity of Raf serine/threonine kinases, including B -Raf (BRAF) .  
The signaling transduction cascade then continues with the phosphorylation and activation 
of MEK1 and MEK2 tyros ine/threonine kinases .  Through phosphorylation, the MEKs 
activate the Erk MAPKs which regulate transcriptional factors that influence 
differentiation, senescence, survival, and proliferation.  
Mutations in the Ras/Raf/MAPK pathway are essential in a number  of cancers including 
the majority of melanomas with ~50% exhibiting BRAF mutations and ~ 20% exhibiting 
NRAS mutations .  In melanoma, these mutations appear at an early stage in tumorigenesis, 
including precursor lesions like benign nevi, and are preserve d through progression .  These 
are activating mutations which result in the Ras/Raf/MAPK pathway constitutively 
signaling for proliferation and survival .  Inhibition of this pathway in tumors with BRAF 
mutations turns off this pathway and shuts down essenti al survival pathways resulting in 
cell death .  BRAF inhibitor (dabrafenib ;  formerly GSK2118436) showed promising results 
with an approximately 2 -fold increase in progression -free survival in a phase III trial, 
which is in a simil ar range as that of  vemura fenib . {Hauschild, 2012}   
Recent studies on ameloblastoma have found BRAF -V600E mutations to be present in the 
majority of cases arising in the mandible .  Two studies have demonstrated that cell lines of 
ameloblastoma are responsive to V600E targeted small  molecule inhibitors in cell 
proliferation assays .   
Two main histologic assays for treatment response will be used :  tumor necrosis and 
phosphorylated -MEK, phosphorylated -ERK, and Ki -67 levels as measured by 
immunohistochemistry .  As mentioned above, sinc e the activation of the Ras/Raf/MAPK 
pathway promotes cell proliferation and survival, blockade of this pathway will result in 
cell decrease in proliferation, death and necrosis .  Furthermore, activation of the 
Ras/Raf/MAPK pathway leads to phosphorylation  of several of the pathway components, 
including MEK and ERK .  These assays for treatment response thus examine both early 
and late effects of Ras/Raf/MAPK pathway inhibition.  
Routine Hemotoxylin -Eosin stained slides from both the pre -treatment biopsy as w ell as 
definitive resection specimens will be scored for the presence of tumor necrosis, which will 
be quantified .  Additionally, unstained slides from both pre - and post - specimens from 
participating institutions will be sent to Stanford University for an alysis of 
phospho -MEK/ERK and Ki -67 staining .  Tumors will be scored, by at least two 
pathologists using percentage positive cells as the primary metric .  The results of the 
IRB-32275  12 of 59 21 August  2018;  Amendment  8 immunohistochemical analysis will be expressed as both raw data in addition to a r atio 
between pre - and post - treatment  
We will also be consenting patients  for permission to sequence the genome of their tumor, 
to publish in public databases anonymized sequence data and to attempt to establich cell 
cultures of tumor specimens if there i s sufficient material to do so .  These studies are 
exploratory and will only be done should there be sufficient specimen from the planned 
biopsies remaining after  the  tumor material for tumor necrosis and phosphorylation assays 
has been obtained.   
3.0 PARTIC IPANT SELECTION AND ENROLLMENT PROCEDURES  
In order to reduce redundancy , we have incorporated the actual eligibility  checklist into the 
body of the protocol .  
3.1 Participant Eligibility Checklist  
A Participant Eligibility Checklist must be completed in its e ntirety for each subject prior 
to registration .  The completed, signed, and dated checklist must be retained in the patient’s 
study file and the study’s Regulatory Binder .  
The study coordinator, treating physician and an independent reviewer must verify t hat the 
participant’s eligibility is accurate, complete, and legible in source records .  A description 
of the eligibility verification process should be included in the EPIC or other Electronic 
Medical Record progress note  or a signed version of the eligib ility checklist must be 
available in EPIC or other Electronic Medical Record for review .  
 
IRB-32275  13 of 59 21 August  2018;  Amendment  8 Eligibi lity criteria in checklist form  
I:  Trial information  
Protocol Title:  A pilot study of dabrafenib  and  trametinib for patients with 
BRAF -mutated  ameloblastoma . 
Protocol Number:  IRB-32275 / ENT0043  
Principal Investigator:  A Dimitrios  Colevas  
II.  Subject Information:  
Subject Name/ID:   
Gender :     Male      Female  
III.  Study Information:  
SRC Approved  IRB Approved  Contract signed  
IV.  Inclusion/Exclusion Criteria  
Inclusion Criteria  Yes No Supporting documents  
1. Histological diagnosis of ameloblastoma .  All 
stages are eligible .  Patients must have evaluable 
disease by R ECIST criteria          
2. BRAF -V600E or other known dabrafenib 
sensitive BRA F mutation in tumor by any 
CLIA -certified lab .  May include, for example, 
Sanger  sequencing, SNaPshot platform, 
immunohistochemistry , Foundation One tests, etc)         
3. At least 18  years old           
4. Life expectancy >  3 months          
5. ECOG performance status ≤ 2 (see Appendix  C)          
IRB-32275  14 of 59 21 August  2018;  Amendment  8 6. Lab values:  
 ANC  > 1.5 x 109/L 
 PLT > 99 x 109/L 
 Hemoglobin  > 8 g/dL 
 Tbili  < 1.6 x ULN   
o Except subjects with known Gilbert’s 
syndrome  
 AST, ALT and alk  phos < 2.6 x upper limit of 
normal  (ULN ) 
 Serum creatinine ≤ 1.5 mg/dL, or i f serum 
creatinine is > 1.5 mg/dL , creatinine 
clearance must be  50 mL/min (calculate 
creatinine clearance using the Cockcroft -Gault 
formula  (see Appendix  D).  
 PR / INR and PTT ≤ 1.3 X ULN .  Subjects 
receiving anticoagulation treatment may be 
allowed to participate with INR established 
within the therapeutic range prior to 
randomization   
 
  
 
       
7. Ability to understand and the willingness to sign a 
written informed consent document          
8. Patients of childbearing potential must agree to 
use effective contraception until at least 6  months 
after trea tment with dabrafenib  and trametinib .  
See exclusion criteria re pregnancy testing          
9. Able to swallow and retain oral medication and 
must not have any clinically significant 
gastrointestinal abnormali ties that may alter 
absorption such as malabsorption syndrome or 
major resection of the stomach or bowels           
10. Left ventricular ejection fraction equal to or 
greater than normal  within 1  month of enro llment .  
ECHO  scans must be used throughout the study .     
Exclusion Criteria   
1. No prior  treatment with agents targeting 
BRAF -mutant tyrosine kinases  or MEK inhibitors  
or radiation of target lesions          
IRB-32275  15 of 59 21 August  2018;  Amendment  8 2. Invasive malignancy other than ameloblastoma 
within 3 years,  excluding curatively treated basal 
cell carcinoma, and other highly curable cancers 
such as  early stage cutaneous squamous cell 
carcinoma ( T1 NO) cervical CIS, early stage 
prostate ca ncer, thyroid cancer,  breast cancer  or 
history of malignancy with confirmed activating 
RAS mutation at any time          
3. Uncontrolled hypertension  (systolic blood 
pressure >  140 mm Hg and diastolic blood 
pressure of >  90 mm Hg which cannot be 
controlled by anti -hypertensive therapy) , CHF, or 
other major medical illness.          
4. Prior allergic reactions attributed to compounds of 
similar chemical or biologic co mposition to 
dabrafenib  or trametinib .         
5. Concomitant use of strong inhibitors 
(eg, ketoconazole, nefazodone, clarithromycin, 
gemfibrozil) or strong inducers ( eg, rifampin,  
phenytoin, carbamazepine, phenobarbital, St 
John’s wort) of CYP3A4 or CYP2C8 .  For a full 
list of  excluded  drugs see  Section  4.1.2 of the 
protocol          
6. Concomitant use of proton pump inhibitors, 
H2-receptor antagonists, antaci ds         
7. Known G6PD deficiency          
8. Pregnant or nursing patients .  Women of 
childbearing potential must have a negative 
SERUM pregnancy test within 1 4 days of 
enrollment .  Women of child -bearing potential 
must agree to use effective contraception for 
14 days prior to enrollment, throughout the 
treatment period and for 4  to 6 months after the 
last dose of study treatment .         
9. EKG with QTcB ( Bazett’s  formula) >  480 ms 
done within 14  days of enrollment          
10. Interstitial lung disease or pneumonitis.          
11. A history of  retinal vein occlusion  (RVO).           
IRB-32275  16 of 59 21 August  2018;  Amendment  8 12. Congestive heart fauilure NYHA  Class III or 
worse  (Marked limitation of physical activity .  
Comfortable at rest .  Less than ordinary activity 
causes fatigue, palpit ation, or dyspnea.)          
13. A history of acute coronary syndromes (including 
myocardial infarction or unstable angina), 
coronary angioplasty, or stenting within 6  months  
or a history or evidence of current  clinically 
significant uncontrolled arrhythmias or 
intra-cardiac defibrillators or abnormal cardiac 
valve morphology ( ≥ Grade  2) documented by 
echocardiogram.   Subjects with Grade  1 
abnormalities (ie,  mild regurgitations/stenosis) 
may be entered.   Subject s with moderate valvular 
thickening are not  eligible. Subjects with atrial 
fibrillation controlled for >  30 days prior to 
dosing are eligible.          
14. Prior systemic anti -cancer treatment 
(chemotherapy, im munotherapy, biologic therapy, 
vaccine therapy or investigational treatment 
within 3  weeks preceding first dose of study 
treatment, or chemotherapy without delayed 
toxicity within 2  weeks preceding first  dose of 
study treatment.          
15. Any serious or unstable pre -existing medical 
conditions, psychiatric disorders or other 
conditions which could interfere with the 
subject’s safety, obtaining informed consent, or 
compliance with study procedures.          
16. A history of Hepatitis  B virus (HBV) or 
Hepatitis  C virus (HCV) infection.  Subjects with 
laboratory evidence of cleared HBV and/or HCV 
will be allowed.           
IRB-32275  17 of 59 21 August  2018;  Amendment  8 V.  Statement of E ligibility  
By signing this form of this trial I verify that this subject is [ eligible  /  ineligible ] for 
participation in the study .  This study is approved by the Stanford Cancer Institute 
Scientific Review Committee, the Stanford IRB, and has finalized financial and contractual 
agreements as required by Stanford School of Medicine’s Research Management Group .   
Treating Physician Signature:  Date:  
Printed Name:  
 
Secondary Reviewer Signature:  Date:  
Printed Name:  
 
Study Coordinator Signature:  Date:  
Printed Name:  
IRB-32275  18 of 59 21 August  2018;  Amendment  8 3.2 Informed Consent Process  
All participants must be provided a consent form describing the study with sufficient 
information for participants to make an informed decision regarding their participation .  
Partici pants must sign the IRB approved informed consent prior to participation in any 
study specific procedure .  The participant must receive a copy of the signed and dated 
consent document .  The original signed copy of the consent document must be retained in 
the me dical record or research file .   
3.3 Study Timeline  
Primary Completion:  
We estimate the study will reach primary completion 27  months from the time the study 
opens to accrual.  
Study Completion:  
The study  will reach study completion 36  months from the time  the study opens to accrual.  
4.0 TREATMENT PLAN  
All patients will have  a diagnosis of ameloblastoma  pathologically confirmed  by the 
participating institution’s department of pathology .  The mutational status of BRAF in the 
tumor must be determined  by any C LIA-certified lab using standard techniques .  These 
may include, for example, Sanger sequencing, SNaPshot platform, immunohistochemistry, 
Foundation One tests, etc.) .  While we are primarily expecting  to identify V600 E 
mutations, other BRAF mutations kn own to confer sensitivity to  dabrafenib   are acceptable 
if approved by the study principal investigator.  
Every patient must have baseline blood chemistries and counts and other eligibility criteria 
as defined in Section  3 done according to the schedule de fined in the study calendar in 
Section  9.  Baseline imaging used to define RECIST v1.1  {Eisenhauer, 2009 } 
measurements are at the discretion of the local investigator .  These will typically be either a 
contrast  enhanced CT or MRI of the relevant anatomy , but PET -CT is also appropriate if 
the  lesion is evaluable by PET -CT per RECIST v1.1 criteria .  To maintain consistency of 
data and quality of science, whatever imaging modality is used at baseline for each patient 
should be used throughout the trial.   Photographic documentation is encouraged but cannot 
substitute for imaging.  
The starting dose for all patients will be :   
Dabrafenib, 150  mg orally twice daily taken at least 1 hour  before or at least 2  hour s 
after a meal .  Dabrafenib comes as 75  mg and 50  mg capsules .  Therefore the initial dose 
will be two 75  mg capsules as specified above .  The second dose of dabrafenib (150  mg) 
should be administered approximately 12  hours after the morning dose .  
Trametinib 2  mg once daily.   
Take the once -daily dose of tr ametinib at approximately the same time each day with either 
the morning dose or the evening dose of dabrafenib .  Study medications should be taken 
orally with approximately 200  mL of water under fasting conditions, either 1  hour  before 
or 2 hour s after a meal.   
IRB-32275  19 of 59 21 August  2018;  Amendment  8 If a subject vomits after taking study medication, the subject should be instructed not to 
retake the dose and should take the next dose as originally scheduled .  
If administration of trametinib is interrupted or permanently discontinued, administra tion of 
dabrafenib may be continued .  If administration of dabrafenib is interrupted or permanently 
discontinued, administration of trametinib may continue .  
If a subject misses a dose of dabrafenib, the subject may take the dose immediately if the 
next do se is scheduled for at least 6  hours later .  If the next scheduled dose of dabrafenib is 
due in less than 6  hours, the subject should skip the dose and resume dabrafenib dosing at 
the next scheduled dose .  If a subject misses a dose of trametinib, the subj ect may take the 
dose immediately if the next dose is scheduled for at least 12  hours later.   
Patients whose tumors are amenable to surgical resection will continue do sing continuously 
for at least 6  weeks  and proceed to surgery between weeks  6 and 7, wit hout dose 
interruption .  Patients undergoing surgical resection will continue dabrafenib and 
trametinib  until it is necessary to take nothing by mouth  in the  hours preceding surgery, 
but ideally the patients will be dosed with dabrafenib  and trametinib  within 12  hour s 
of the surgical resection .   Patients whose tumors are grossly completely resected will not 
resume dabrafenib  and trametinib .  Patients whose tumors are not resected  completely 
have the option to resume the dabrafenib  and trametinib  at the d ose they were receiving 
immediately prior to surgery  if  ALL of the following criteria  are met:   
1. Prior to surgery the patient  did not have AEs or progression which necessitated  
dabrafenib  or trametinib  cessation.   
2. The patient has recovered from s urgery without unexpected complication.   
3. At least 1 week  has passed since surgery.   
4. The patient has evaluable residual tumor .  
5. No more than 6  week s has elapsed since surgery.   
Patients whose disease is judged to be not amenable to resection will c ontinue dabrafenib  
and trametinib  indefinitely as long as there has not been tumor progression either by 
RECIST  v1.1 or clinical progression criteria, there have not been unacceptable adverse 
events and  the patient has not decided to discontinue for other  reasons.   
Clinical evaluations  for protocol purposes will take place according to the schedule 
defined in Section  9.  Dose modifications will be according to the guidelines in Section  6.  
4.1 General Concomitant Medication and Supportive Care Guidelines  
4.1.1 Perm itted Medications and Non -Drug Therapies  
The investigator must be informed as soon as possible about any medication taken from the 
time of screening until the end of investigational drug administration .  Documentation of  
concomitant medication(s), includi ng dietary supplements, taken during the study will be 
recorded in the  patient medical record according to the schedule specified in  Section  9.  
The minimum requirement is that drug name, dose, and the dates of administration are to 
be recorded .  
Subject s should receive full supportive care during the study, including transfusions of 
blood and blood products, and treatment with antibiotics, anti -emetics, anti -diarrheals, and 
analgesics, and other care as deemed appropriate, and in accordance with their in stitutional 
IRB-32275  20 of 59 21 August  2018;  Amendment  8 guidelines .  Use of anticoagulants such as warfarin is permitted however, c aution should 
be exercised  and additional International Normalized Ratio (INR) monitoring is 
recommended when dabrafenib is used concomitantly with warfarin .  See Sectio n 4.1.3 for 
guidelines concerning concomitant  warfarin and dabrafenib administration.  
Radiation skin injury has been reported with concurrent use of dabrafenib and radiation .  It 
is recommended that dabrafenib and trametinib be held for 7  days before and 2 days after 
XRT .  
Medicinal products that increase gastric pH should be used with caution when 
administered with dabrafenib .  See Section  4.1.3 for details.   
4.1.2 Prohibited Medications and Non -Drug Therapies   
The use  of certain medications  ( see T able 2 below ) and il licit drugs within 28 days or 
5 half-lives, whichever is shorter, prior to and during  da brafenib study treatment . will not 
be allowed .  
The following medications or non -drug therapies are prohibited while on treatment in this 
study:   
 Other anti -cancer therapies;   
 Other investigational drugs;   
 Herbal remedies ( eg, St John’s  wort);   
 Dabrafenib is metabolized primarily by Cytochrome P450 (CYP) 2C8 and CYP3A4 .  
Co-administration of dabrafenib with ketoconazole, a CYP3A4 inhibit or, or with 
gemfibrozil, a CYP2C8 inhibitor, resulted in increases in dabrafenib AUC of 71% and 
47%, respectively .  Drugs that are strong inhibitors or inducers of CYP3A and CYP2C8  
(see list in the table below)  may only be used under special circumstances (e.g .  as a 
single use fo r a procedure) while treatment with study drug is interrupted as they may 
alter dabrafenib concentrations ;  consider therapeutic substitutions for these 
medications .  Approval of the protocol principal  investigator is required and must 
be documented in the se situations .  
IRB-32275  21 of 59 21 August  2018;  Amendment  8 Table  2 :  Prohibited Medications  
PROHIBITED – Strong inducers of CYP3A or CYP2C8, since concentrations of dabrafenib 
may be decreased  
Class/Therapeutic Area  Drugs/Agents  
Antibiotics  Rifamycin class agents ( eg, rifampin, rifabutin, rifape ntine),  
Anticonvulsant  Carbamazepine,  oxcarbazepine phenobarbital, phenytoin, 
s-mephenytoin  
Miscellaneous  bosentan, St -John’s wort  
PROHIBITED – Strong inhibitors of CYP3A, or CYP2C8 since concentrations of dabrafenib 
may be increased  
Class/Therapeuti c Area  Drugs/Agents  
Antibiotics  Clarithromycin, telithromycin, troleandomycin  
Antidepressant  Nefazodone  
Antifungals  Itraconazole, ketoconazole, posaconazole, voriconazole  
Hyperlipidemia  Gemfibrozil   
Antiretroviral  ritonavir, saquinavir, atazanavir  
Miscellaneous  Conivaptan  
 
4.1.3 Medications to be used  with Caution  
The following medications should be used with caution as their concentrations may be 
altered by dabrafenib or they may alter dabrafenib concentrations:  
 Drugs that are moderate inhibitors or indu cers of CYP3A and CYP2C8 as they may 
alter concentrations of dabrafenib.  
 Dabrafenib has been shown to induce CYP3A4 and CYP2C9 in vivo using midazolam 
(CYP3A4 substrate) and S -warfarin (CYP2C9 substrate) .  Dabrafenib is an in vitro 
inducer of CYP2B6 and ot her enzymes such as CYP2C8, CYP2C19, UDP -glucuronyl 
transferases .  Transporters may also be affected .  Co-administration of dabrafenib and 
medications which are affected by the induction of these enzymes (including warfarin) 
and transporters may result in loss of efficacy .  If co-administration of these 
medications is necessary, investigators should monitor subjects for loss of efficacy or 
consider substitutions of these medications .  A partial list of these medications is 
provided in  Table 2 above .   
 Thera peutic level dosing of warfarin can be used with close monitoring of PT/INR by 
the site .  Warfarin exposure has been shown to decrease (37% decrease) due to 
dabrafenib -mediated enzyme induction .  Conversely, if dabrafenib dosing is reduced, 
interrupted, or  discontinued, warfarin exposure may be increased .  Thus, warfarin 
dosing may need to be adjusted based on PT/INR during and after treatment with 
dabrafenib .  Prophylactic low dose warfarin may be given to maintain central catheter 
patency .   
IRB-32275  22 of 59 21 August  2018;  Amendment  8   Infrom Dabraf enib solubility is pH -dependent with decreased solubility at higher pH .  
Drugs such as proton pump inhibitors that inhibit gastric acid secretion to elevate 
gastric pH may decrease the solubility of dabrafenib and reduce its bioavailability .  No 
clinical s tudy has been conducted to evaluate the effect of pH on dabrafenib 
pharmacokinetics .  In an ad -hoc analysis, no differences in C max and AUC were noted 
between subjects who reported taking pH -elevating products relative to other subjects .  
Due to the theore tical risk that pH -elevating agents may decrease oral bioavailability 
and exposure to dabrafenib, these medicinal products that increase gastric pH 
should be used with caution when administered with dabrafenib.  
4.2 Criteria for Removal from Study  
Patients shou ld have dabrafenib discontinued for  unacceptable adverse events , clinically  
unacceptable or RECIST v1.1 defined progression, or patient withdraws  of consent .  For 
patients who stop dabrafenib because of unacceptable AEs or progression of disease , 
providers  may proceed  to surgical resection as clinically indicated .  Patients who have not 
withdrawn consent to be studied should have all planned restaging  and secondary tissues 
analyses performed per protocol  prior to surgery and  on the surgical specimens res ected at 
the time of surgery .  Patients should be followed for protocol related AEs for 4  week s after 
the last dabrafenib dose unless  another systemic anti - cancer agent has been initiated.  
5.0 STUDY  AGENT  INFORMATION  
5.1 Study  Agent s  
Dabrafenib is  a kinase inhib itor FDA approved for  the treatment of patients with 
unresectable or metastatic melanoma with BRAF -V600E mutation as detected by an 
FDA -approved test .  It comes  in 50  mg and 75  mg capsules .  Active ingredient :  
dabrafenib .  Inactive ingredients :  colloida l silicon dioxide, magnesium stearate, 
microcrystalline cellulose .  Capsule shells contain :  hypromellose, red iron oxide (E172), 
titanium dioxide (E171).  
Trametinib is a FDA -approved  kinase inhibitor for the treatment of patients with 
unresectable or meta static melanoma with BRAF -V600E or -V600K mutations as detected 
by an FDA -approved test .  Tablets are supplied as 0.5  mg and 2  mg tablets for oral 
administration .  Each 0.5  mg tablet contains 0.5635  mg trametinib dimethyl sulfoxide 
equivalent to 0.5  mg of trametinib non -solvated parent .  Each 2  mg tablet contains 
2.254  mg trametinib dimethyl sulfoxide equivalent to 2  mg of trametinib non -solvated 
parent .  The inactiv e ingredients are t ablet core:  mannitol, microcrystalline cellulose, 
hypromellose, croscarm ellose sodium, magnesium stearate (vegetable source), sodium 
lauryl sulfate, colloidal silicon dioxide ;  and c oating :  hypromellose, titanium dioxide, 
polyethylene glycol, polysorbate 80 (2  mg tablets), iron oxide yellow (0.5  mg tablets), iron 
oxide red (2  mg tablets).  
Dabrafenib  and trametinib  will be dosed as specified in Section  4 of this protocol , with 
dose modifications in Section  6. 
IRB-32275  23 of 59 21 August  2018;  Amendment  8 5.2 Availability  
Dabrafenib  and trametinib  will be obtained  from Novartis and distributed to all 
investigational sites acco rding to  a pharmacy appendix to be developed prior to protocol 
activation . 
5.3 Agent Ordering  
Dabraf enib and trametinib  will be ordered by site investigational pharmacies according to  
guidelines to be developed prior to protocol activation and included in th e pharmacy 
appendix section .   
5.4 Agent Accountability  
Access to dabrafenib  and trametinib  will be restricted according to the standard operating 
procedures  of the investigational pharmacies of each collaborating institution ’s pharmacy .  
Drug accountability w ill similarly be according to each institution’s standard operating 
procedures . 
5.5 Combination Dosage and Administration and Handling and Storage Guidelines  
Dabrafenib and trametinib must be dispensed and administered in accordance with the 
protocol, and only to subjects enrolled in the study.  Dabrafenib and trametinib must be 
stored in a secure area under the appropriate physical conditions for the product.  Study 
medication is to be stored at the temperature specified on the label.  Maintenance of a 
temperature log (manual or automated) is required.  Access to and administration of 
dabrafenib and trametinib will be limited to the investigator and authorized site staff.   
6.0 DOSE MODIFICATIONS  
6.1 Dose Modification for General Toxicities  
General guidelines regar ding management and dose reduction for adverse events that are 
considered by the investigator to be related to study treatment and for which specific 
guidelines do not apply are provided in the t able below .  These guidelines are intended 
primarily for toxi cities not easily managed with routine supportive care .  For example, 
alopecia is not an indication for dose modification, nor is grade 2 nausea and vomiting that 
can be easily managed with anti -emetics .   
Table 3 :  Recommended dabrafenib and trametinib do se level reductions  
DABRAFENIB  TRAMETINIB  
Dose Level  Dose/Schedule  Dose Level  Dose/Schedule  
Full dose  150 mg twice daily  Full dose  2 mg once daily  
First reduction  100 mg twice daily  First reduction  1.5 mg once daily  
Second reduction  75 mg twice daily  Second reduction  1 mg once daily  
Third reduction  50 mg twice daily  Third reduction  0.5 mg once daily  
IRB-32275  24 of 59 21 August  2018;  Amendment  8 Table 4 :  Dose Modification Guidelines - General  
CTCAE Grade  Occurance  Action and Dose Modification  a,b 
Grade 1 or 
Grade  2 
(tolerable)  N/A Continue study  treatment at same dose level (no dose 
modification) and monitor as clinically indicated  
Grade 2 
(Intolerable) or  
Grade 3  1st, 2nd or 
3rdoccurrence  Interrupt study treatment until toxicity resolves to ≤  grade  1 
then restart at next lower dose level  
4th or greater 
occurrence  Discontinue treatment  
Grade 4  1st occurrence  Interrupt study treatment until toxicity resolves to ≤ grade  1 
or baseline then restart at next lower dose level or 
discontinue at discretion of investigator  
2nd occurrence  Interrupt study treatment until toxicity resolves to ≤ grade  1 
or baseline then restart at two dose levels lower than the 
starting dose or discontinue at discret ion of investigator and 
after discussion with the medical monitor.  
3rd occurrence  Discontinue treatment  
a. Treatment should be discontinued if more than 3 dose reductions are required  
b. Approval from the protocol PI is required to restart study treatment aft er  ≥ 21 days  
When an individual’s adverse reactions are under effective management, dose re -escalation 
following the same dosing steps as de -escalation may be considered .  
These are general guidelines and investigators should always use clinical judgmen t in 
determining dose adjustments for any individual patient .  Some toxicities may require 
hospitalization for stabilization, additional work -up, and consultation with a specialist 
before treatment can be restarted .  Specific adverse events and recommended  management 
include  the following:   
6.2  Dose reductions  for AEs of interest in patie nts taking dabrafenib and trametinib  
6.2.1 Plantar - Palmar Erythrodysesthesia  (Hand foot syndrome, PPES) – Measures for 
PPES should include:   
Lifestyle modification :  avoidance of hot water ;  traumatic activity ;  constrictive 
footwear ;  or excessive friction on the skin .  Adopt  the use of thick cotton socks and 
gloves, and shoes with padded insoles .  
Symptomatic treatments :  apply moisturizing creams frequently ;  topical keratoly tics 
(eg, urea 20  to 40% cream ;  salicylic  acid 6%;  tazarotene  0.1%  cream ;  
fluorouracil  5% cream), clobetasol  propionate  0.05% ointment for erythematous  areas;  
topical  lidocaine  2%;  and/or systemic pain medication such as nonsteroidal 
anti-inflam matory  drugs  (NSAIDs);  codeine ;  and pregabalin for pain.   
Dose modification may also be required .  
IRB-32275  25 of 59 21 August  2018;  Amendment  8 6.2.2 Pancreatitis   
In the event of abdominal pain or suspected pancreatitis, amylase and lipase laboratory 
samples should be collected for confirmation of the diagno sis.  Patients should be 
closely monitored when re -starting dabrafenib after an episode of pancreatitis . 
6.2.3 Uveitis  and ocular events (see below for specific guidelines)  
Ophthalmological exams will be required at baseline, Week  6 and annually thereafter.   
Episodes of visual changes have been observed in subjects receiving trametinib, 
dabrafenib, and combination therapy .  An ophthalmologist should be consulted if 
changes in vision develop .  However, if the visual changes are clearly unrelated to study 
treatment  (eg, allergic conjunctivitis), then monitor closely as it may be  reasonable to 
defer ophthalmic examination . 
Treatment with dabrafenib has been associated with the development of uveitis, 
including iritis .  Monitor patients for visual signs and symptoms ( such as, change in 
vision, photophobia and eye pain) during therapy .  Special attention should be given to 
retinal findings ( eg, retinal pigment epithelial detachment  (RPED) or retinovascular 
abnormalities (ie, branch or central retinal vein occlusions  (RVO).  Guidelines regarding 
management and dose reduction for visual changes and/or ophthalmic examination 
findings considered to be related to study treatment are provided in the below tables:  
IRB-32275  26 of 59 21 August  2018;  Amendment  8 Table 5 :  Management and Dose Modification Guidelines for Visual  Changes and/or 
Ophthalmologic Examination Findings  
CTCAE 
Grade  a Adverse Event Management  Action and Dose Modification  
  
Grade 1  b  Consult ophthalmologist 
within 7 days of onset  
  If dilated fundus examination cannot be 
performed within 7 days of onset, i nterrupt 
trametinib until RPED and RVO can be 
excluded by retina specialist/ophthalmologist .  If 
subject is receiving trametinib/dabrafenib 
combination ther apy dabrafenib may be 
continued  
 If RPED and RVO excluded, continue (or 
restart) trametinib at same d ose level  
 If RPED suspected or diagnosed :  see RPED 
dose modification table Y below ;  report as 
SAE  if diagnosed  
 If RVO diagnosed :  Permanently discontinue 
trametinib and report as SAE  
 
 Grade 2 and  
 Grade 3   Consult ophthalmologist 
immediately  
 Interrupt t rametinib .  If 
subject is receiving 
trametinib/dabrafenib 
combination therapy 
dabrafenib may be continued   If RPED and RVO excluded,  restart trametinib at 
same dose level  
 If RPED diagnosed , see RPED dose 
modification table below ;  report as SAE  
 If RVO diagn osed:  Permanently discontinue 
trametinib  and report as SAE  
  
Grade 4   Consult ophthalmologist 
immediately  
 Interrupt trametinib .  If 
subject is receiving 
trametinib/dabrafenib 
combination therapy 
dabrafenib may be continued   If RPED and RVO excluded,  may consider 
restarting trametinib at same or reduced dose 
after discussion with study medical monitor  
 If RVO or RPED diagnosed, permanently 
discontinue trametinib and report as SAE  
c. Refers to CTCAE Version 4.0 ‘Eye disorders – Other, specify’  
d. If visual chan ges are clearly unrelated to study treatment ( eg, allergic conjunctivitis), monitor closely but 
ophthalmic examination is not required.  
IRB-32275  27 of 59 21 August  2018;  Amendment  8 Table 6 :  Recommended dose modifications for trametinib for retinal pigment epithelial 
detachments (RPED)  
CTCAE Grade a Action and Dose Modification  
Grade  1 RPED  (Asymptomatic ;  clinical 
or diagnostic observations only)   Continue treatment with retinal evaluation monthly 
until resolution .  If RPED worsens follow instructions 
below  
 
Grade  2-3 RPED  (Symptomatic with  
mild to  moderate decrease in visual acuity ;  
limiting instrumental ADL)  
  Interrupt trametinib  
 Retinal evaluation monthly  
 If improved to ≤ Grade 1, restart trametinib at lower 
dose (reduced by 0.5  mg) or discontinue in patients 
taking trametinib 1  mg daily  
e. Refe rs to CTCAE Version 4.0 ‘Retinopathy’  
6.2.4 Hyperglycemia  
Hyperglycemia requiring an increase in the dose of, or initiation of insulin or oral therapy 
can occur with dabrafenib .  Monitor serum glucose levels as clinically appropriate during 
treatment with dabraf enib in subjects with pre -existing diabetes or hyperglycemia .  
Advise patients to report symptoms of severe hyperglycemia such as excessive thirst or 
any increase in the volume or frequency of urination.  
Investigators should always err on the side of cauti on in these settings if treatment -related 
toxicity is a possibility .  
6.2.5 Pyrexia  
Episodes of pyrexia have been observed in subjects receiving dabrafenib monotherapy, 
and is increased in incidence and severity in subjects receiving dabrafenib in combinat ion 
with trametinib .  In a minority of cases the pyrexia was accompa nied by symptoms such 
as severe  chills ;  dehydration ;  hypotension ;  and dizziness or weakness .  
Subjects should be instructed on the importance of immediately reporting febrile 
episodes .  In the event of a fever, the subject should be instructed to take anti -pyretics 
(eg, ibuprofen or acetaminophen) as appropriate to control fever .  The use of oral 
corticosteroids should be considered in those instances in which anti -pyretics are 
insuffici ent.  Monitor serum creatinine and other evidence of renal function during and 
following severe events of pyrexia.   
Guidelines regarding management and dose modifications for pyrexia considered to 
be related to study treatment provided below.   
IRB-32275  28 of 59 21 August  2018;  Amendment  8 Table 7:  Ma nagement and Dose Modification Guidelines for Pyrexia  
Adverse 
Event  Adverse Event Management  Action and Dose Modification  
Pyrexia : a All Events:  
 Clinical evaluation for infection and 
hypersensitivity  c  
 Laboratory work -up c 
 Hydration as required  d 
1st Event b: 
 Administer anti -pyretic treatment  as 
clinically indicated and initiate prophylactic 
treatment if associated with rigors, renal 
failure, dehydration or hypotension  e 
2nd Event  f 
 Within 3 days of onset of pyrexia  
o Optimize anti -pyretic therapy  
o Conside r oral corticosteroids (ie, 
prednisone 10  mg) for at least 5  days or as 
clinically indicated  f 
Subsequent Events :   
 Within 3 days of onset of pyrexia:  
o Optimize oral corticosteroid dose as 
clinically indicated for recalcitrant 
pyrexia  f  
o If corticosteroids have been tapered and 
pyrexia recurs, restart steroids  
o If corticosteroids cannot be tapered consult 
medical monitor  1st Event:   
 Interrupt dabrafenib  
 Continue trametinib  
 Once pyrexia resolves to baseline, restart 
dabrafenib at the same dose level  
o If fever  was associated with rigors, renal 
failure, dehydration or hypotension, 
reduce dabrafenib by one dose level  g 
2nd Event:  
 Interrupt dabrafenib  
 Continue trametinib  
 Once pyrexia resolves to baseline, restart 
dabrafenib at the same dose level  
o If fever was asso ciated with rigors, renal 
failure, dehydration or hypotension, 
reduce dabrafenib by one dose level  g 
Subsequent Events:  
 Interrupt dabrafenib  
 Continue trametinib  
 Once pyrexia resolves to baseline, restart 
dabrafenib reduced by one dose level  g 
 If dabrafenib  must be reduced to <  50 mg 
BID, permanently  discontinue 
dabrafenib.  Trametinib may be 
continued  
a. Pyrexia is defined as a body temperature equal to or above 38.5 Celsius or 101.3ºFahrenheit.   
b. For subjects experiencing pyrexia complicated by rigors , severe chills, etc., a clinical evaluation and laboratory work -up is 
mandatory for each event;  anti -pyretic treatment should be started immediately at the first occurrence and prophylactic 
anti-pyretic treatment is recommended  
c. Thorough clinical exami nation for signs and symptoms of infection or hypersensitivity is required;  laboratory work -up 
should include full -blood -count, electrolytes, creatinine, blood urea nitrogen (BUN), C -reactive protein (CRP), 
liver-function tests, blood culture, and urine c ulture.  
d.   Oral hydration should be encouraged in subjects without evidence of dehydration.  Intravenous hydration is recommended 
in subjects experiencing pyrexia complicated by dehydration/hypotension.  
e.   Anti-pyretic treatment may include acetaminoph en, ibuprofen, or suitable anti -pyretic medication according to institutional 
standards.  Prophylactic anti -pyretic treatment may be discontinued after three days in the absence of pyrexia  
f.  In subject experiencing pyrexia complicated by rigors, severe c hills, etc., which cannot be controlled with anti -pyretic 
medication, oral corticosteroids should be started at the 2nd event and doses should be gradually increased for subsequent 
events.  
g.   Dabrafenib should be reduced by one dose level after three epi sodes of pyrexia complicated by rigors, severe chills, etc., 
which cannot be managed by best supportive care and increasing doses of oral steroids.  Escalation of dabrafenib is allowed 
if no episode of pyrexia is observed in the 4  weeks subsequent to dose reduction.  
IRB-32275  29 of 59 21 August  2018;  Amendment  8 6.2.6 Malignancies  
Cuta neous squamous cell carcinoma ( cuSCC)  
Cases of cuSCC (which include those classified as keratoacanthoma or mixed 
keratoacanthoma subtype) have been observed in subjects treated with dabrafenib .  
Approximately 70 % of events occ urred within the first 12  week s of treatment with a 
median time to onset of 8  week s.  These should be surgically removed according to 
institutional practices .  Dose modification or interruption of study treatment is not required 
for cuSCC or KA, however cu SCC should be reported as an SAE .  In addition, a biopsy of 
the lesion should be taken, where possible, and a summary of the results submitted to the 
PI.  Patients should be instructed to immediately inform their physician if new lesions 
develop .  Skin exa mination should be performed prior to initiation of dabrafenib and during 
treatment with dabrafenib, every 2 months throughout therapy .  Monitoring should 
continue every 2  months for 6  months following discontinuation of dabrafenib or until 
initiation of a nother anti -neoplastic therapy .   
6.2.7 New Primary Melanoma  
New primary melanomas have been reported in patients treated with dabrafenib .  These 
were identified primarily within the first 5  months of therapy and did not require treatment 
modification oth er than excision .  Monitoring for skin lesions should occur as described for 
cuSCC.  
6.2.8 Non-Cutaneous Malignancies  
In vitro  experiments have demonstrated paradoxical activation of MAP -kinase signaling  in 
BRAF wild type cells with RAS mutations when expos ed to BRAF inhibitors, which may 
lead to increased risk of non -cutaneous malignancies in patients treated with dabrafenib .  
Cases of RAS -driven malignancies have been seen with BRAF inhibitors .  Patients should 
be monitored as clinically appropriate.  
New n on-cutaneous malignancies should be reported as a SAE .  A biopsy of the new 
malignancy should be taken, where possible, and submitted for further analyses with the 
results provided to the PI .   
6.2.9  Renal Insufficiency  
Cases of renal insufficiency have o ccurred in subjects receiving dabrafenib and the 
combination of dabrafenib and trametinib .  Prior to start of study treatment, concomitant 
medications should be reviewed for the potential risk of inducing nephrotoxicity and 
concomitant medications should b e modified if clinically possible .  Guidelines regarding 
management and dose reduction for renal insufficiency considered to be related to study 
treatment by the investigator are provided below.  
IRB-32275  30 of 59 21 August  2018;  Amendment  8 Table 8 :  Management and Dose Modification Guidelines for Ren al Insufficiency  
Serum Creatinine 
Level  Adverse Event Management  Action and Dose 
Modification  
Serum creatinine 
increase >  0.2 mg/dL 
(18 umol/L)  but 
 0.5 mg/dL 
(44 umol/L) above 
baseline   Recheck serum creatinine within 1  week  
 Serum creatinine increase > 1  week :  contact Novartis  
Medical Monitor .  If elevation persists beyond 4  week s, 
recommend evaluation (consider renal biopsy) for etiology ;  
consider nephrology consultation.  
 If pyrexia is present, treat pyrexia as per guidelines  a  Continue study 
treatmen t at the 
same dose level  
Serum creatinine 
increase >  0.5 mg/dL 
(44 umol/L) above 
baseline or  
serum creatinine 
>2 mg/dL 
(> 177 umol/L)   Monitor serum  creatinine ≥  2 times per week  
 Hospitalization may be necessary   if serum creatinine 
cannot be monitored frequently  
 If pyrexia is present, treat pyrexia per guidelines  a  
 Consult nephrologist if clinically indicated  
 Perform renal biopsy if clinically indi cated, for example:  
o Renal insufficiency persists despite volume repletion  
o Subject has new rash or signs of hypersensitivity (such as 
elevated eosinophil count)   Interrupt study 
treatment until 
serum creatinine 
recovers to 
baseline  
 Restart with study 
treatme nt b 
a. NSAIDs can induce renal insufficiency, especially in subjects with dehydration ;  encourage oral fluids or 
consider intravenous fluids as clinically indicated .  See guidelines for pyrexia Section  
b. Investigator may restart at either the same or a  reduced dose level .  Escalation of study treatment to previous dose 
level is allowed if another episode of renal insufficiency does not occur after 4  week s of dose reduction .   
IRB-32275  31 of 59 21 August  2018;  Amendment  8 6.2.10  Guidelines for Prolonged QTc  
Guidelines for dose modification and stopping cr iteria due to QTC -prolongation are below.  
Table 9:  Withholding and Stopping Criteria for QTc B-Prolongation  
QTc-
Prolongation  a  Action and Dose Modification  
 QTcB   
≥ 501 msec   or 
 Uncorrected 
QT > 600 msec  
or 
 QTcB  > 530 
msec for subjects 
with bundle 
branch block   Interrupt study treatment until QTcB prolongation resolves to Grade 1 or baseline  
 Test serum potassium, calcium, phosphorus and magnesium .  If abnormal, corr ect 
per routine clinical practice to within normal limits  
 Review concomitant medication usage for a prolonged  QTc 
 If event resolves, restart study treatment at current dose level  b 
 If event does not resolve, permanently discontinue study treatments .  Consi der 
evaluation with cardiologist.  
 If event recurs, permanently discontinue study treatment  
 Consider evaluation with cardiologist  
Abbreviations:  msec = milliseconds; QTc = QT interval on electrocardiogram  
a. Based on average QTc value of triplicate ECGs.  F or example, if an ECG demonstrates a prolonged QT 
interval, obtain two or more ECGs over a brief period, and then use the averaged QTc values of the three 
ECGs to determine if study treatments should be interrupted or discontinued.  
b. If the QTc prolongation resolves to grade 1 or baseline, the subject may resume study treatment if the 
investigator and Novartis medical monitor agree that the subject will benefit from further treatment  
IRB-32275  32 of 59 21 August  2018;  Amendment  8 6.2.11  Guidelines for Pneumonitis  
Pneumonitis has been observed in subject s receiving trametinib in combination with 
dabrafenib .  To reduce the risk of pneumonitis, subjects will be monitored closely for 
symptoms, evaluated with imaging and functional tests .  Dose modification and supportive 
care guidelines for pneumonitis are d escribed below.  
Table 10 :  Management and Dose Modification Guidelines for Pneumonitis  
CTCAE 
Grade  Adverse Event Management  Action and Dose Modification  
 
Grade 1   CT scan (high -resolution with lung windows) 
recommended  
 Clinical evaluation and laboratory wo rk-up for 
infection  
 Monitoring of oxygenation via pulse -oximetry 
recommended  
 Consultation of pulmonologist recommended   Continue trametinib at current dose  
Grade 2   CT scan (high -resolution with lung windows)  
 Clinical evaluation and laboratory work -up for  
infection  
 Consult pulmonologist  
 Pulmonary function tests –if < normal, repeat 
every 8  week s until ≥ normal  
 Bronchoscopy with biopsy and/or BAL 
recommended  
 Symptomatic therapy including corticosteroids 
if clinically indicated   Interrupt trametinib until recovery to 
grade ≤1  
 Restart with  trametinib reduced by one 
dose level  
 Escalation to previous  dose level after 
4 week s and consultation with medical 
monitor possible  
 If no recovery to grade ≤1 within 
4 week s, permanently discontinue study 
treatment  
Grade 3   CT scan (high -resolution with lung windows)  
 Clinical evaluation and laboratory work -up for 
infection  
 Consult pulmonologist  
 Pulmonary function tests -if < normal, repeat 
every 8  week s until ≥ normal  
 Bronchoscopy with biopsy and/or BAL if 
possible  
 Symptomatic therapy including corticosteroids 
as clinically indicated   Interrupt trametinib until recov ery to 
grade ≤1  
 After consultation with medical monitor, 
study treatment may be restarted reduced 
by one dose level  
 If no recovery to grade ≤1 within 
4 week s, permanently discontinue study 
treatment  
Grade 4   Same as grade 3   Permanently discontinue trametin ib  
6.2.12  Guidelines for Cardiomyopathy  
Across clinical trials of trametinib at the recommended dose 11% of patients developed 
evidence of cardiomyopathy (decrease in LVEF below institutional lower limits of  normal 
with an absolute decrease in LVEF ≥  10% below baseline) and 5% demonstrated a  
decrease in LVEF below institutional lower limits of normal with an absolute decrease in 
LVEF of ≥  20% below baseline.  
IRB-32275  33 of 59 21 August  2018;  Amendment  8 Assess LVEF  before initiation of trametinib, one month after initiation and then at  
3-month int ervals while on treatment .  Withhold treatment if absolute LVEF value 
decreases by 10% from pre -treatment values and is less than the lower limit of normal .  
Permanently discontinue for  symptomatic cardiomyopathy or persistent, asymptomatic 
LVEF dysfuncti on that does not resolve within 4  week s 
Table 11 :  Combination Dose Modification Guidelines  and Stopping Criteria for 
LVEF  Decrease  
Clinic  LVEF -drop (%) or  
CTCAE grade  Action and Dose Modification  
 
Asymptomatic   
Absolute decrease of 
> 10% in LVEF 
compared  to baseline 
and ejection fraction 
below the institution’s  
LLN   Interrupt trametinib and repeat ECHO within 2  week s a,b  
 If the LVEF recovers  within 4  week s (defined as LVEF 
≥ LLN and absolute decrease ≤  10% compared to baseline)   
 Consult with Novartis me dical monitor and request 
approval for re -start 
 If approved, re -start treatment with TMT reduced by 
one dose level  
 Repeat ECHO at 2, 4, 8, and 12 weeks after re -start, 
continue at intervals of 12 weeks  
 If  LVEF does not recover  within 4  week s 
    Consult wi th cardiologist  
 Permanently discontinue trametinib  
 Report as SAE  
 Repeat ECHO after 2, 4, 8, 12, and 16 weeks, or 
until resolution  
Symptomatic  c Grade 3 :  resting LVEF 
39 to 20% or >  20% 
absolute reduction from 
baseline   Permanently discontinue trametinib  
 Interrupt dabrafenib  d  
 Report as SAE  
 Consult with cardiologist  
 Repeat ECHO after 2, 4, 8, 12, and 16 weeks, or  until 
resolution  b,d Grade 4 :  resting 
LVEF  < 20% 
Abbreviations:  CTCAE = Common Terminology Criteria for Adverse Events; ECHO = echocardiog ram; LLN = lower 
limit of normal; LVEF = left ventricular ejection fraction;  
a. If ECHO does not show LVEF recovery after 2 weeks, repear ECHO two weeks later.  
b. If recurrent episodes of LVEF reduction occur in subjets receiving DRB monotherapy, consult medica l monitor.  
c. Symptoms may include :  dyspnea, orthopenea, and other signs and symptoms of pulmonary congestion and edema.  
d. Once LVEF recovers, including resolution of symptoms, restart of dabrafenib monotherapy only can be considered 
in consultation with Novar tis medical monitor.  
IRB-32275  34 of 59 21 August  2018;  Amendment  8 6.2.13  Treatment of Study Treatment Overdose  
In the event of a dabrafenib overdose, defined as administration of more than 300  mg as a 
single dose or 600  mg per day (the highest dose tested in clinical studies to date), and/or a 
trame tinib overdose, defined as administration of more than 3.0  mg once daily the 
investigator should closely monitor the subject for AEs/SAEs and laboratory abnormalities .  
The investigator will use clinical jud gment to treat any overdose .  Hemodialysis is not  
expected to enhance the elimination of either dabrafenib or trametinib as both are highly 
bound to plasma proteins.  
Decisions regarding dose interruptions or modifications will be made by the investigator in 
consultation with the PI based on the clinical evaluation of the subject.  
Information regarding the quantity of the excess dose as well as the duration of the 
overdosing should be documented in the case report  forms . 
7 ADVERSE EVENTS AND REPORTING PROCEDURES  
7.1 Potential Adverse Events  
7.1.1 Dabrafenib pot ential  adverse effects  
Please see  the FDA package insert for dabrafenib .  Additional  information can also be 
found in the Investigator Brochure section titled “Summary of Data and Guidance for the 
Investigator .”  Below are tables from the 2015 package summarizing anticipated  AEs:  
IRB-32275  35 of 59 21 August  2018;  Amendment  8 Table 12 :  Selected Common Adverse Reactions Occurring in > 10% (All Grades) or ≥  2% 
Grades 3 or 4) of Patients Treated with dabrafenib N = 187  
 
 
Table 1 3: Incidence of Laboratory Abnormalities Increased from Baseline Occurring a t a 
Higher Incidence in Patients Treated with dabrafenib (Tafinlar)  in a single agent melanoma 
trial [Between -Arm Difference of ≥  5% (All Grades) or ≥  2% (Grades 3 or 4)] a 
IRB-32275  36 of 59 21 August  2018;  Amendment  8 
 
 
Other clinically important adverse reactions observed in <  10% of patients (N  = 586) 
treated with dabrafenib were:  
 Gastrointestinal Disorders :  Pancreatitis .   
 Immune System Disorders :  Hypersensitiv ity manifesting as bullous rash  
 Renal and Urinary Disorders :  Interstitial nephritis.  
IRB-32275  37 of 59 21 August  2018;  Amendment  8 Table 14: Select Adverse Reactions Occurring in ≥10%  (All Grades) of 
Patients Treated with dabrafenib( tafinlar)  in Combination with Trametinib  
 
IRB-32275  38 of 59 21 August  2018;  Amendment  8 Table 15: Select Treatment -Emergent Laboratory Abnormalities Occurring at ≥10% (All 
Grades) of Patients Receiving dabrafenib (Tafinlar) in combination with trame tinib.  
 
7.1.2 Trametinib potential adverse effects  
Please see the FDA package insert for trametinib .  Additional information can also be 
found in the Investigator Brochure section titled “Summary of Data and Guidance for the 
Investigator” .  Below are tabl es from the 201 5 package insert summarizing anticipated AEs  
IRB-32275  39 of 59 21 August  2018;  Amendment  8 Table 16:  Selected Adverse Reactions Occurring in ≥10% of Patients Receiving 
trametinib  (Mekinist) and at a Higher Incidence (≥ 5%) than in the Chemotherapy  
Arm  or ≥ 2% (Grades  3 or 4) Adverse  Reactions   
 
Other clinically important adverse reactions observed in less than or equal to 10% of patients 
(N = 329) treated with  Mekinist  (trametinib ) were:   
Cardiac  Disorders: Bradycardia  
Gastrointestinal  Disorders: Dry mouth  
Infections and Infestations: Folliculitis, rash pustular, cellulitis   
Musculoskeletal and Connective Tissue Disorders: Rhabdomyolysis  
Nervous System Disorders: Dizziness, dysgeusia  
Ocular Disorders: Blurred vision, dry eye  
IRB-32275  40 of 59 21 August  2018;  Amendment  8 Table 17:  Percent -Patient Incidence of Laboratory Abnormalities Occurring at  
a Higher Incidence in Patients Treated With trametinib  (Mekinist)  in Trial  1  
[Between Ar m Difference of ≥  5% (All Grades) or ≥  2% (Grades 3 or 4)  a] 
 
IRB-32275  41 of 59 21 August  2018;  Amendment  8 Table 18:  Incidence of Adverse Reactions Occurring in ≥10% (All Grades) of Patients 
Receiving trametinib (MEKINIST_ with Dabrafenib and at a Higher Incidence* than in  
Patients Receiving Single -Agent Dabrafenib  
 
Other clinically important adverse reactions for trametinib observed in less than 10% of patients 
receiving trametinib in combination with dabrafenib ( N = 559) were:  
Cardiac Disorders: Bradycardia  
Musculoskeletal Disorders: Rhabdomyoly sis 
IRB-32275  42 of 59 21 August  2018;  Amendment  8 Table  19:  Treatment -Emergent Laboratory Abnormalities Occurring at ≥  10% (All  Grades) of 
Patients Receiving trametinib  (Mekinsit ) with Dabrafenib and at a Higher Incidence* than in 
Patients Receiving Single -Agent  Dabrafenib  
 
7.2    Adverse Event Reporting  
For detailed  guidan ce on reporting adverse events, refer to the  adverse event SOP  
(Appendix  B) 
Reporting  
To ensure patient safety, every SAE, regardless of suspected causality, occurring after the 
patient has provided the main informed consent and until at least 30  days after the patient 
has stopped study treatment must be reported to Novartis within 24  hours  of learning of its 
occurrence.  
IRB-32275  43 of 59 21 August  2018;  Amendment  8 Any SAEs experienced after this 30  days period should only be reported to Novartis if the 
investigator suspects a causal relationship to t he study treatment .  Recurrent episodes, 
complications, or progression of the initial SAE must be reported as follow -up to the 
original episode within 24  hours  of the investigator receiving the follow -up information .  
An SAE occurring at a different time i nterval or otherwise considered completely unrelated 
to a previously reported one should be reported separately as a new event.  
Information about all SAEs is collected and recorded on the Serious Adverse Event Report 
Form; all applicable sections of the fo rm must be completed in order to provide a clinically 
thorough report .  The investigator must assess and record the relationship of each SAE to 
each specific study treatment (if there is more than one study treatment), complete the SAE 
Report Form in Engli sh, and send the completed, signed form by fax within 24  hours  to the 
oncology Novartis Drug Safety and Epidemiology (DS&E) department - Fax: 
(877-778-9739) .  The original copy of the SAE Report Form and the fax confirmation sheet 
must be kept with the cas e report form documentation at the study site .  Follow -up 
information is sent to the same contact(s) to whom the original SAE Report Form was sent, 
using a new SAE Report Form stating that this is a follow -up to the previously reported 
SAE and giving the d ate of the original report .  Each re -occurrence, complication, or 
progression of the original event should be reported as a follow -up to that event regardless 
of when it occurs .  The follow -up information should describe whether the event has 
resolved or c ontinues, if and how it was treated, whether the blind was broken or not, an 
whether the patient continued or withdrew from study participation.  
If the SAE is not previously documented in the Investigator’s Brochure or Package Insert 
(new occurrence) and i s thought to be related to the Novartis study treatment, an oncology 
Novartis Drug Safety and Epidemiology (DS&E) department associate may urgently 
require further information from the investigator for Health Authority reporting .  Novartis 
may need to issu e an Investigator Notification (IN), to inform all investigators involved in 
any study with the same drug that this SAE has been reported .  Suspected Unexpected 
Serious Adverse Reactions (SUSARs) will be collected and reported to the competent 
authorities and relevant ethics committees in accordance with Directive 2001/20/EC or as 
per national regulatory requirements in participating countries.  
Pregnancies  
To ensure patient safety, each pregnancy occurring while the patient is on study treatment 
must be rep orted to Novartis within 24  hours  of learning of its occurrence .  The pregnancy 
should be followed up to determine outcome, including spontaneous or voluntary 
termination, details of the birth, and the presence or absence of any birth defects, congenital 
abnormalities, or maternal and/or newborn complications.  
Pregnancy should be recorded on a Clinical Trial Pregnancy Form and reported by the 
investigator to the oncology Novartis Drug Safety and Epidemiology Department (DS&E) .  
Pregnancy follow -up should be  recorded on the same form and should include an 
assessment of the possible relationship to the study treatment any pregnancy outcome .  Any 
SAE experienced during pregnancy must be reported on the SAE Report Form.  
Adverse events will be graded according to  CTCAE v4.0 3.  Both Serious and Non -Serious 
Adverse Events will be clearly noted in source documentation and listed on study specific 
Case Report Forms (CRFs) .  The Protocol Director (PD) or designee will assess each 
IRB-32275  44 of 59 21 August  2018;  Amendment  8 Adverse Event (AE) to determine whether  it is unexpected according to  Section  7.1 of the 
protocol and related to dabrafenib  and trametinib .   
SAEs and all subsequent follow -up reports will be reported to the CCTO Safety Office 
regardless of the event’s relatedness to the investigation .  Followi ng review by the CCTO 
Safety Officers, any events  meeting the IRB definition of “Unanticipated  Problem ” will be 
reported to the IRB using eProtocol within 10 working days of the review, or within 5 
working days for deaths or life -threatening experiences .  SAEs will be relayed back to 
Novartis.  
7.2.1 SAE definitions  
Serious adverse event (SAE) is defined as one of the following:  
 Is fatal or life-threatening  
 Results in persistent or significant disability/incapacity  
 Constitutes a congenital anomaly/birth defe ct 
 Is medically significant, ie, defined as an event that jeopardizes the patient or may 
require medical or surgical intervention to prevent one of the outcomes listed above  
 Requires inpatient hospitalization or prolongation of existing hospitalization,  
Note that hospitalizations for the following reasons should not be reported as serious 
adverse events:  
 Routine treatment or monitoring of the studied indication, not associated with any 
deterioration in condition  
 Elective or pre -planned treatment for a pre -existing condition that is unrelated to the 
indication under study and has not worsened since signing the informed consent  
 Social reasons and respite care in the absence of any deterioration in the patient’s 
general condition  
Note that treatment on an eme rgency outpatient basis that does not result in hospital 
admission and involves an event not fulfilling any of the definitions of a SAE given above 
is not a serious adverse event  
7.3 Pregnancy  
Pregnancy Testing and Prevention  
The need for a screening pregn ancy test depends on whether a female subject is of 
childbearing potential or non -childbearing potential.  
A female of non -childbearing potential ( ie, physiologically incapable of becoming 
pregnant) is defined as any female who has had a hysterectomy, bilat eral oophorectomy 
(ovariectomy), bilateral tubal ligation or tubal occlusion, or is post -menopausal.   
A practical definition accepts menopause after 1 year without menses with an appropriate 
clinical profile, eg, age appropriate, >  45 years in the absence  of hormone -replacement 
therapy (HRT).  In questionable cases, the subject must have a follicle -stimulating 
hormone  (FSH) value >  40 mIU/mL and an estradiol value <  40 pg/mL (<  140 pmol/L).  
IRB-32275  45 of 59 21 August  2018;  Amendment  8 A female of child -bearing potential is defined as any female who d oes not meet the criteria 
of non -childbearing potential as described in the previous paragraph.   
If a female subject is of childbearing potential, she must have a serum β-human chorionic 
gonadotropin  (HCG) pregnancy test performed within 14  days prior to randomization.  
Subjects with a positive pregnancy test result must be excluded from the study.  Subjects 
with a negative pregnancy test result must agree to use an effective contraception method 
as described below throughout study treatment and until 4  months after the last dose of 
study treatment.  
Novartis acceptable contraceptive methods, when used consistently and in accordance with 
both the product label and the instructions of the physician, are as follows:  
 An intrauterine device with a documented fai lure rate of less than 1% per year.  
 Male partner sterilization prior to the female subject’s entry, and this male is the sole 
sexual partner for that female.  
 Complete abstinence from sexual intercourse for 14 days prior to enrollment, 
throughout study trea tment, and for at least 4 months after the last dose of study 
treatment. Abstinence is only acceptable when in line with the preferred and usual 
lifestyle of the subject.  Periodic abstinence (eg , calendar, ovulation, 
symptothermal, post -ovulation methods,  etc) and withdrawal are not acceptable 
methods of contraception.  
 Double -barrier contraception: condom and occlusive cap (diaphragm or cervical/vault 
caps) with a vaginal spermicidal agent (foam/gel/cream/suppository).  
Note:  Hormonal -based methods ( eg, oral contraceptives) are not permitted as 
contraception due to potential drug -drug interactions with dabrafenib.   
Female subjects who are lactating must discontinue nursing prior to the first dose of study 
treatment and must refrain from nursing throughout the treatment period and for 4  months 
following the last dose of study treatment.  
If a subject becomes pregnant during the treatment period of the study, the study treatments 
should be stopped immediately.  
8 CORRELATIVE/  SPECIAL STUDIES  
8.1 Laboratory Correlat ive Studies  
8.1.1 Collection of Specimen(s)  
Biopsy specimens will be collected per normal institutional methods for biopsy and 
surgical resection procedures.  
8.1.2 Handling of Specimens(s)  
At the time of the baseline biopsy, endpoint biopsy, and/or resection specimen,  the tissue 
will be handled and processed by routine tissue protocol at the pathology laboratory of the 
institution performing the procedure .  Standard morphologic assessment of the tissue 
(including H&E stain) will be performed by the pathology laboratory  of the institution 
performing the procedure with an emphasis to avoid decalcification of the tumor material, 
if possible.  
IRB-32275  46 of 59 21 August  2018;  Amendment  8 8.1.3 Shipping of Specimen(s)  
The archived biopsy or representative portions of the resection specimen, including 
formalin fixed paraffin e mbedded block and matching H&E slide, will be sent to the 
laboratory of Dr  Robert  West at the Site Performing Correlative Study 
(Stanford  Cancer  Institute) by overnight courier at room temperature .  Once archived, the 
tissue is stable at room temperature.  
8.1.4 Site(s) Performing Correlative Study  
The Site Performing Correlative Study is the laboratory of Dr Robert  West at the Stanford 
Cancer Institute at the Stanford University Medical Center .  Dr West’s laboratory will be 
responsible for all the correlative stu dy tests.  
8.1.5 Coding of specimens for privacy protection  
The specimens will be coded at the time of receipt in the laboratory of Dr Robert  West .  
The specimen will be given a 5 -digit number with no relationship to the subjects’  HIPPA 
data.  The key for the cod ed specimens and the patient data will be kept by Dr Robert  West 
in a locked office.  
IRB-32275  47 of 59 21 August  2018;  Amendment  8 9 STUDY CALENDAR  
 Pre-
Study  Wk 
1 Wk 
2 Wk 
3 Wk 
 4 Wk 
5 Wk 
6 Wk 
7 Wk 
8 Wk 
9 Wk 
10 Wk 
11 Wk 
12 Off-Study  d 
Dabrafenib  
 Dabrafenib will be 
administered twice daily as 
specified  in Section  4 until 
surgical resection  FOR SUBJECTS 
NOT  UNDERGOING 
SURGICAL RESECTION:  
dabrafenib will continue 
until disease progression or 
intolerance   
Trametinib  
 Trametinib will be 
administered daily as 
specified in Section  4 until 
surgical resection  FOR SUBJECTS 
NOT  UNDERGOING 
SURGICAL RESECTION:   
trametinib will continue 
until disease progression or 
intolerance   
Informed consent  X              
Demographics  X              
Medical history  X              
Biopsy of tumor for 
correlative studies  X       X g       
Surgical resection for 
patients with 
resectable tumors, and 
tissue collection for 
correlative studies          X        
Concurrent meds  X X X a  
 
Physical exam  X   X   X   X a   X a X 
Vital signs  X   X   X   X a   X a X 
Height  X              
Weight  X              
Performance status  X              
CBC w/diff, plts  X   X   X   X a   X a X 
Serum chemistry b X   X   X   X a   X a X 
EKG within 14  days 
of enrollment  X              
ECHO cardiogram 
within 1  month of 
enrollment  X   X         X f  
IRB-32275  48 of 59 21 August  2018;  Amendment  8  Pre-
Study  Wk 
1 Wk 
2 Wk 
3 Wk 
 4 Wk 
5 Wk 
6 Wk 
7 Wk 
8 Wk 
9 Wk 
10 Wk 
11 Wk 
12 Off-Study  d 
Adverse event 
evaluation.  See 
Section  7 for expected 
AEs and Section  6 for 
dose modification 
rules.  X   X   X   X a   X a X a 
Tumor measurements  
X Tumor measurements are repeated every 6  weeks.  After 
Week  7, tumor measurements are repeated every 
6 to 9 weeks. Documentation (radiologic) must be 
provided for patients removed from study for progressive 
disease.  X d 
Radiologic evaluation 
(CT, MRI, X -ray) 
X Tumor measurements are repeated every 6  weeks.  After 
Week  7, tumor measurements are repeated e very 
6 to 9 weeks. Documentation (radiologic) must be 
provided for patients removed from study for progressive 
disease.  X d 
Serum Pregnancy 
testing within 14  days 
of enrollment  X   
Ophthalmologic 
examination.  See 
Section  6 on 
guidelines for visual 
chang es and exam 
source sheet in 
appendix  X      X e        
a: Only for patients continuing on dabrafenib and/ or  trametinib who have not undergone surgery.   
b: Albumin, alkaline phosphatase, total bilirubin, bicarbonate, BUN, calcium, chloride, creatinine, glucose, 
phosphorus, potassium, total protein, AST, ALT, sodium.  
d: Off-study evaluation.   
e: Ophthalmologic exams to be repeated  annually.  
f: Every 3 months while on trametinib . 
g. For subjects not undergoing surgical  resection.  
 
 
10 MEASUREMENTS  
Primary Outcome Measure :  Response rate according to RECIST v1.1 at 6  week s  
 RECIST  v1.1 response rate , specifically, the sum of CR and PR per RECIST  v1.1  
 Time Frame :  6 weeks  
 Safety Issue :  Not a  safety issue  primary endpoint  
IRB-32275  49 of 59 21 August  2018;  Amendment  8 10.1 Primary and Secondary Outcome measur es 
The primary endpoint will be tumor response rate (CR + PR)  at 6 weeks .  We intend to use 
modified RECIST  v1.1 criteria  {Eisenhauer, 2009} , knowing that since this patient 
population will include presurgical subjects, we will be unable to obtain respons e 
confirmation following the surgical resection of tumors . {Eisenhauer, 2009 #311}  
10.1.1  Measurement Definition  
The definition we will use for the  primary endpoint of response will be per the 
RECIST  v1.1 criteria, with the exception that for patients undergoing surgical resection 
there will be no confirmatory imaging  as this would be irrelevant following  surgical 
resection . CR, PR, SD , PR are  all defined in the cited RECIST  reference and are widely 
available and therefore will not be repeated here .  
10.1.2  Measurement M ethods  
Standard CT or MRI scans and physical exam, per RECIST  v1.1 criteria, will be used to 
measure  tumors for purposes of response assessment.   To maintain consistency of data and 
quality of science, whatever imaging modality is used at baseline for each  patient should be 
used throughout the trial .  
10.1.3  Measurement Time Points  
Initial response  evaluation for the primary endpoint will be at 6  week s.  For patients not 
undergoing surgical resection, follow -up imaging will be every  6 to 9 weeks , which we 
consider  to be standard of care.  
10.2 Secondary Outcome  
10.2.1  Tumor  necrosis  
One secondary outcome will be percent  of tumor necrosis at the time of endpoint biopsy or 
surgical resection .  We intend to use this outcome with criteria established for treatment 
response in other  tumors .   
10.2.2  Measurement Definition  
The definition we will use for the first secondary endpoint of response will be evaluation of 
extent of tumor necrosis by H&E slide review .  This will be performed on either the 
endpoint biopsy or the resection specimen .   
10.2.3  Measurement Methods  
Routine H&E slide review will be used to measure extent of tumor necrosis for purposes of 
response assessment .  Percentage of tumor necrosis by volume will be assessed as routinely 
done with other solid tumors such as osteosarcoma .  The biopsy slide or multiple slides of 
the resection specimen will be examined and the volume of the necrosis compared to the 
volume of the total tumor will be determined by the centrally reviewing pathologists and 
percentage readouts of tumor necrosis, in i ncrements of 10%, will be determined .  In 
addition to measuring tumor necrosis the slide review will also estimate therapy effect on 
intact cells by estimating the percent cells with therapy -associated nuclear atypia.  
IRB-32275  50 of 59 21 August  2018;  Amendment  8 10.2.4  Measurement Time Points  
Tumor necrosis  evaluation for this secondary endpoint will be at the time of the endpoint 
biopsy or the surgical resection.  
10.2.5  Response Review  
Tumor necrosis evaluation will be centralized review by the study co -investigator, Robert 
West, and at least one designee with sub stantial experience with tumor necrosis evaluation .  
Disagreements concerning response assessment between the PI and the second reviewer 
will be adjudicated by a board certified pathologist with tumor necrosis evaluation 
experience.  
10.3 Secondary Outcome – Proliferation index  
A second secondary outcome will be proliferation index as measured by Ki67 percent 
positivity at the time of endpoint biopsy or surgical resection .  We intend to use this 
outcome as measured with immunohistochemistry with criteria establis hed for assessment 
of proliferation index for other tumors .   
10.3.1  Measurement Definition  
The definition we will use for the second secondary endpoint of response will be evaluation 
of percent proliferation index by Ki67 immunohistochemistry .  This will be perf ormed on 
the initial pre -treatment biopsy and either the endpoint biopsy or the resection specimen.  
10.3.2  Measurement Methods  
Proliferation index evaluation will be performed in the laboratory of Dr .  Robert West on 
the initial pre -treatment biopsy and either th e endpoint biopsy or the resection specimen .  
Ki-67 immunohistochemistry will be scored by at least two pathologists using percentage 
positive cells as the primary metric .  The results of the immunohistochemical analysis will 
be expressed as both raw data in addition to a ratio between pre - and post - treatment .  All 
pathological evaluations will be done centrally by the pathology co - investigators, Robert 
West and Jonathan Pollack or their designees.  
10.3.3  Measurement Time Points  
Proliferation index evaluation fo r this secondary endpoint will be at the time of the 
endpoint biopsy or the surgical resection.  
10.3.4  Response Review  
Proliferation index evaluation will be centralized review by the study co -investigator, 
Robert West and Jonathan Pollack and at least one design ee with substantial experience 
with proliferation index evaluation .  Disagreements concerning response assessment 
between the PI and the second reviewer will be adjudicated by a board certified pathologist 
with proliferation index evaluation experience.  
10.4 Secondary Outcome – Phosphorylation of MEK/ERK  
A second secondary outcome will be expression of phosphorylation of MEK and ERK as 
measured by phospho -MEK/ERK positivity at the time of endpoint biopsy or surgical 
resection .  We intend to use this outcome as m easured with immunohistochemistry using 
antibodies specific for phospho -MEK/ERK and total MEK/ERK (either phosphorylated or 
IRB-32275  51 of 59 21 August  2018;  Amendment  8 un-phosphorylated) with criteria established for assessment of protein expression by 
immunohistochemistry for other tumors .   
10.4.1  Measur ement Definition  
The definition we will use for the second secondary endpoint of response will be evaluation 
of protein expression by immunohistochemistry .  This will be performed on the initial 
pre-treatment biopsy and either the endpoint biopsy or the re section specimen.  
10.4.2  Measurement Methods  
Immunohistochemistry evaluation for MEK/ERK will be performed in the laboratory of 
Dr.  Robert West on the initial pre -treatment biopsy and either the endpoint biopsy or the 
resection specimen .  Immunohistochemistry wi ll be scored by at least two pathologists 
using percentage positive cells and intensity of staining as the primary metrics .  The results 
of the immunohistochemical analysis will be expressed as both raw data in addition to a 
ratio between pre - and post - treatment .  All pathological evaluations will be done centrally 
by the pathology co - investigators, Robert West and Jonathan Pollack or their designees.  
10.4.3  Measurement Time Points  
Immunohistochemistry evaluation for MEK/ERK for this secondary endpoint will be a t the 
time of the endpoint biopsy or the surgical resection.  
10.4.4  Response Review  
Immunohistochemistry evaluation for MEK/ERK will be centralized review by the study 
co-investigator, Robert West and Jonathan Pollack and at least one designee with 
substantial ex perience with protein expression evaluation .  Disagreements concerning 
response assessment between the PI and the second reviewer will be adjudicated by a board 
certified pathologist with protein expression evaluation experience.  
11 REGULATORY CONSIDERATIONS  
11.1 Institutional Review of Protocol  
The protocol, the proposed informed consent and all forms of participant information 
related to the study (e.g .  advertisements used to recruit participants) will be reviewed and 
approved by the Stanford IRB and Stanford Ca ncer Institute Scientific Review Committee 
(SRC) .  Any changes made to the protocol will be submitted as a modification and will be 
approved by the IRB prior to implementation .  The Protocol Director will disseminate the 
protocol amendment information to a ll participating investigators .  All participating sites 
will similarly have the  informed consent document and protocol  reviewed and approved by 
their local IRB and scientific review committee .  There is to be only one version of the 
protocol to be used ac ross all participating sites and no site can individually modify or 
amend the protocol at their site alone .  That is, al l protocol amendments and modifications 
must be reviewed and approved by al l institutions’ relevant review boards.  
11.2 Data and Safety Monit oring Plan :   
The Stanford Cancer Institute Data and Safety Monitoring Committee (DSMC) will be the 
monitoring entity for this study .  The DSMC will audit study -related activities to determine 
whether the study has been conducted in accordance with the pro tocol, local standard 
operating procedures, FDA regulations, and Good Clinical Practice (GCP) .  This may 
IRB-32275  52 of 59 21 August  2018;  Amendment  8 include review of the following types of documents participating in the study :  regulatory 
binders, case report forms, eligibility checklists, and sour ce documents .  In addition, the 
DSMC will regularly review serious adverse events and protocol deviations associated with 
the research to ensure the protection of human subjects .  Results of the DSMC audit will be 
communicated to the IRB s of all participat ing institutions and  the appropriate regulatory 
authorities at the time of continuing review, or in an expedited fashion, as needed.  
11.3 Data Management Plan  
11.3.1  Data Collection  
Data  collection for this study will be via REDCap , a password protected HIPAA complian t 
web- based electronic data capture  system .  Prior to opening this study at any site, case 
report forms for the collection of a ll relevant required data  will be developed and relevant 
site staff trained on the access and use of REDCap .  Eligibility for ea ch patient enrolled 
will be confirmed by the PI or designee centrally before authorization to enroll and patient 
number assignment is made via REDCap .  The Protocol Director, or his/her designee, will 
prepare and maintain adequate and accurate participant case histories with observations and 
data pertinent to the study .  At each participating site, that site’s PI or designee is 
responsible for collecting and storing in one central location copies of all primary clinical 
documents and be prepared to transmit  these documents via secure electronic means  for 
remote audit and review .  All sites should also be able to readily access actual primary 
documentation, either electronically or in paper form, for on-site audit purposes.  
11.3.2  Data  Submission responsibility  
It is the responsibility of each site PI to ensure that all investigators and designees at that 
site understand  and are trained in all the relevant procedures for data collection and 
submission .  For the purposes of site data submission compliance, data will be considered 
delinquent and such delinquency reported to that site’s IRB if the data for any required 
routine  evaluation is not  submitted within 4  week s after  the relevant visit,  test, or 
assessment has been completed or resulted.  
11.3.3  Multicenter Guidelines  
The overall PI is responsible for distribution of all IND action letters and safety reports to 
all participating institutions .   
12 STATISTICAL CONSIDERATIONS  
12.1 Statistical Design  and primary analysis  
We propose a two stage Optimal design per Simon , et al.  (Sim on   R ,1989 .  Controlled 
Clinical Trials .  10:1-10), and using the UNC calculator:  
http://www.cscc.unc.edu/cscc/aivanova/SimonsTwoStageDesign.aspx  
The null hypothesis that the  true response rate is 0.05 will be tested against a one -sided 
alternative .  In the first stage, 9 evaluable patients will be accrued .  If there is less than one 
response (defined in Section  10.1)  in these 9 patients, the study will be stopped .  If at the 
time of the 9th patient’s enrollment there has not been at least one centrally  documented 
response , accrual  will stop until responses have been centrally determined for the first nine 
patients .  Otherwise, 8 additional evaluable patients will be accrued fo r a total of 
IRB-32275  53 of 59 21 August  2018;  Amendment  8 17 evaluable patients .  The null hypothesis will be rejected if 3 or more responses are 
observed in 17  patients .  We will allow for up to 11  patients in the first stage and up to 
10 patients in the second stage to account for patient drop -out / uneavaluable pati ents.  This 
design yields a type  I error rate of 0.0466 and power of 0.8122 when the true response rate 
is 0.25 .  We believe that anything below a response rate of 25% would not be clinically 
meaningful given the potential risks of dabra fenib  and trametinib .  The likelihood of 
stopping early if  the null hypothesis is true will be 0.63 .  A response rate of 25% or higher, 
in the context of other promising secondary endpoint  results such  as a high % of tumor  
necros is, would warrant further s tudy.  
12.2 Secondary Analysis  
We will determine secondary responses for :  1) tumor necrosis ;  2) prolife ration index ;  and 
3) ERK/MEK phos phorylation .  These assays will be exploratory and not subjected to a 
prospective statistical plan for analysis .  Tumor nec rosis % will be estimated according  the 
standard surgical pathology techniques.  Proliferation index will be measured  by 
percentage of cells in mitosis and Ki 67 staining per standard surgical pathiology assays.  
The ratio of unphosphorylated  to phosphory lated ERK and MEK will be done using 
standard phosphorylation specific antibodies  on tumor  tissue specimens in Dr  West’s lab 
according to his lab’s SOPs.   See Section  10 for details.  
12.3 Sample Size  
11 to 21 patients  (9 to 17 evaluable pateints) .  See Section  12.1 
12.4 Accrual estimates   
We estimate 3  to 6 patients will be accrued among collaborating institutions annually .  This 
is a very rare disease, incidence 0.5/ million estimated .  Stanford sees and evaluates outside 
pathology on about 5 cases per year and our  collaborating centers estimate about the same .  
12.5 Feasibility and safety assessment  
Because this is a very rare disea se, our assumptions concerning the ability to accrue in a 
timely way are considerably uncertain .  Therefore , at each annual review, should  the 
accrual in the preceding year be less than 3  patients, we will re-evaluate the feasibility of  
conducting this protocol and either modify the protocol or close the protocol.  Also as part 
of that annual review, if the cum ulative rate of completion of 6  weeks of dabrafenib and 
trametinib treatment as specified in Section  4 is not achieved in at least 2/3 of all subjects , 
we will review the feasibility of administering treatment on this study a nd modify or close 
the protocol.  
Safety data, collected as spe cified in the study calendar in section nine, will be summarized 
in tabular form using the CTCAE  v4.03 for AE description and grading.  Cumulative safety 
data and all SAE reports will be reviewed by investigators both annually and at the end of 
the first s tage of accrual.  Should less than 2/3 of patients  enrolled  at any of these annual 
reviews or first stage analysis not complete the protocol treatment as stipulated in this 
protocol, the protocol will either be amended to address these safety issues or the  protocol 
will be closed to further accrual.  High -grade AEs alone are not to be  construed as an 
indication to stop accrual or amend the protocol as long as treatment of those AEs per 
standards of care and modifications per Section  6 allow for completion o f treatment as 
specified in Section  4.  Reporting of SAEs is covered in Section  7.2. 
IRB-32275  54 of 59 21 August  2018;  Amendment  8 13 REFERENCES  
Acosta D , Affolder T, Akimoto H,  et al.  (2003) .  “Search for the supersymmetric partner of the 
top quark in dilepton events from pp collisions at square root o f s=1.8 TeV. ”  Phys Rev Lett .  
90(25 Pt 1) :251801.  
Amzerin M , Fadoukhair Z, Belbaraka R , et al.  (2011) .  “Metastatic ameloblastoma responding to 
combination chemotherapy :  case report and review of the literature. ”  J Med Case Rep .  5:491. 
Anand  SV, Davey WW, Cohen B , et al.  (1967) .  “Tumours of the jaw in West Africa .  A review 
of 256 patients. ”  Br J Surg .  54(11) :901-917.  
Barnes L .  (2005) .  Pathology and Genetics of Head and Neck Tumours , IARC :296-300. 
Becelli R , Carboni A, Cerulli G,  et al.  (2002) .  “Mandibular ameloblastoma :  analysis of surgical 
treatment carried out in 60 patients between 1977 and 1998. ”  J Craniofac Surg .  13(3) :395-400;  
discussion 400.  
Becelli R , Morello R, Renzi G,  et al.  (2011) .  “Treatment of recurrent mandibular  ameloblastoma 
with segmental resection and revascularized fibula free flap. ”  J Craniofac S urg.  
22(3) :1163 -1165 . 
Brastianos PK, et al.  (2016) .  “Dramatic Response of BRAF -V600E Mutant Papillary 
Craniopharyngioma to Targeted Therapy .”  J Natl Cancer Inst .  108. 
Bhasker S .  (1981) .  “Synopsis of Oral Pathology. ” 
Brazis  PW, Miller NR, Lee AG,  et al.  (1995) .  "Neuro -ophthalmologic Aspects of 
Ameloblastoma."  Skull Base Surg .  5(4):233-244. 
Brown  NA, Rolland D, McHugh JB,  et al.  (2014) .  “Activating FGFR2 -RAS-BRAF mutations in 
ameloblastoma. ”  Clin Cancer Res .  20(21) :5517 -5526.  
Carlson  ER, Marx RE.  (2006) .  “The ameloblastoma :  primary, curative surgical management. ”  J 
Oral Maxillofac Surg .  64(3) :484-494. 
Chai Y , Jiang X, Ito Y,  et al.  (2000) .  “Fate of  the mammalian cranial neural crest during tooth 
and mandibular morphogenesis. ”  Development .  127(8) :1671 -1679 . 
Ciment  LM, Ciment AJ. (2002) .  "Malignant ameloblastoma metastatic to the lungs 29 years after 
primary resection :  a case report."  Chest .  121(4):1359 -1361 . 
Cusack  JW.  (1827) .  “Report of the amputations of the lower jaw. ”  Dublin Hosp Rec .  4:1-38. 
Daley  TD, Wysocki GP, Pringle GA , et al.  (1994) .  “Relative incidence of odontogenic tumors 
and oral and jaw cysts in a Canadian population. ”  Oral Surg Oral Med Oral Pathol .  
77(3) :276-280. 
Eisenhauer  EA, Therasse P, Bogaerts J,  et al.  (2009) .  “New response evaluation criteria in solid 
tumours :  revised RECIST guideline (version 1.1). ”  Eur J Cancer .  45(2) :228-247. 
Eliasson  AH, Moser RJ, 3rd, Te nholder MF .  (1989) .  ”Diagnosis and treatment of metastatic 
ameloblastoma. ”  South Med J .  82(9) :1165 -1168 . 
Escandell I, et al.  (2015) .  “Effective treatment with Dabrafenib and Trametinib for a 
BRAF -mutated metastatic dedifferentiated malignant spindle cell neoplasm. ”  J Eur Acad 
Dermatol Venereol . 
Flaherty KT, et al.  (2012) .  “Improved survival with MEK inhibition in BRAF -mutated 
melanoma .”  N Engl J Med .  367:107-114. 
Gall JA, Sartiano GP, Shreiner DP , et al.  (1975) .  “Ameloblastoma of the mandible w ith 
pulmonary metastasis. ”  Oncology 32(3 -4):118-126-126. 
IRB-32275  55 of 59 21 August  2018;  Amendment  8 Gardner  DG, Pecak AM. (1980) .  “The treatment of ameloblastoma based on pathologic and 
anatomic principles. ”  Cancer .  46(11) :2514 -2519 .  
Gerzenshtein J , Zhang F, Caplan J,  et al.  (2006) .  “Immedia te mandibular reconstruction with 
microsurgical fibula flap transfer following wide resection for ameloblastoma. ”  J Craniofac 
Surg .  17(1) :178-182. 
Gortzak  RA, Latief BS, Lekkas C,  et al.  (2006) .  “Growth characteristics of large mandibular 
ameloblastoma s:  report of 5 cases with implications for the approach to surgery. ”  Int J Oral 
Maxillofac Surg . 35(8) :691-695. 
Grunwald V , Le Blanc S, Karstens JH,  et al.  (2001) .  “Metastatic malignant ameloblastoma 
responding to chemotherapy with paclitaxel and carbo platin. ”  Ann Oncol .  12(10) :1489 -1491 . 
Hasim  FW, Poon CC, Smith AC .  (2007) .  “Prolonged survival with confirmed metastatic 
pulmonary ameloblastoma. ”  Int J Oral Maxillofac Surg .  36(10) :953-955. 
Hauschild A, et al.  (2012) .  “Dabrafenib in BRAF -mutated m etastatic melanoma :  a multicentre, 
open -label, phase 3 randomised controlled trial. ”  Lancet .  380(9839) :358-365. 
Hertog D , Bloemena E, Aartman IH,  et al.  (2012) .  “Histopathology of ameloblastoma of the 
jaws;  some critical observations based on a 40  years single institution experience. ”  Med Oral 
Patol Oral Cir Bucal .  17(1) :e76-82. 
Ivy RH , Churchill HR. (1930) .  “The need of a standardized surgical and pathological 
classification of tumors and anomalies of dental origin. ”  Am Assoc Dent Sch Trans .  7:240-245. 
Kaye FJ, et al.  (2015).  “Clinical and radiographic response with combined BRAF -targeted 
therapy in stage 4 ameloblastoma.”  J Natl Cancer Inst .  107(1):378 . 
Kurppa KJ, CatonJ, Morgan PR, et al.  (2014) .  “High frequency of BRAF -V600E mutations in  
ameloblastoma. ”  J Pathol .  232(5) :492-498. 
Larsson A , Almeren H. (1978) .  "Ameloblastoma of the jaws .  An analysis of a consecutive series 
of all cases reported to the Swedish Cancer Registry during 1958 -1971."  Acta Pathol Microbiol 
Scand A .  86a(5) :337-349. 
Long GV, et al.  (2015).  “Dabrafenib and trametinib versus dabrafenib and placebo for Val600 
BRAF -mutant melanoma:  a multicentre, double -blind, phase  3 randomised controlled trial.”  
Lancet .  386(9992):444 -451. 
Lu Y, Xuan M, Takata T .  (1998) .  “Odontogenic tumors .  A demographic study of 759 cases in a 
Chinese population. ”  Oral Surg Oral Med Oral Pathol Oral Radiol Endod .  86(6) :707-714. 
Malassez L .  (1885) .  “Sur les role des débris épithéliaux paradentaires .”  Arch Physiol Norm 
Pathol .  5,6:309-340, 379 -449. 
Mosadomi, A .  (1975) .  “Odontogenic tumors in an African population .  Analysis of twenty -nine 
cases seen over a 5 -year period. ”  Oral Surg Oral Med Oral Pathol .  40(4) :502-521. 
Ndukwe  KC, Adebiyi EK, Ugboko VI,  et al.  (2010) .  “Ameloblastic carcinoma :  a multicenter 
Nigerian study. ”  J Oral Maxillofac Surg .  68(9) :2111 -2114 . 
Pandya NJ, Stuteville OH .  (1972) .  “Treatment of ameloblastoma .”  Plast Reconstr Surg .”  
50(3) :242-248. 
Ramadas K , Jose CC, Subhashini J,  et al.  (1990) .  “Pulmonary met astases from ameloblastoma of 
the mandible treated with cisplatin, adriamycin, and cyclophosphamide. ”  Cancer .  
66(7) :1475 -1479 . 
Regezi  JA, Kerr DA, Courtney RM (1978) .  “Odontogenic tumors :  analysis of 706 cases. ”  J Oral 
Surg .  36(10) :771-778. 
IRB-32275  56 of 59 21 August  2018;  Amendment  8 Reichart  PA, Philipsen HP, Sonner S .  (1995) .  “Ameloblastoma :  biological profile of 3677 
cases. ”  Eur J Cancer B Oral Oncol .  31b(2) :86-99. 
Robert C, et al.  (2015) .  “Improved overall survival in melanoma with combined dabrafenib and 
trametinib. ”  N Engl J Med .  372(1) :30-39. 
Schafer  DR, Thompson LD, Smith BC,  et al.  (1998) .  “Primary ameloblastoma of the sinonasal 
tract:  a clinicopathologic study of 24 cases. ”  Cancer .  82(4) :667-674. 
Sham E , Leong J, Maher R,  et al.  (2009) .  “Mandibular ameloblastoma :  clinic al experience and 
literature review. ”  ANZ J Surg .  79(10) :739-744. 
Slootweg  PJ, Muller H. (1984) .  “Malignant ameloblastoma or ameloblastic carcinoma. ”  Oral 
Surg Oral Med Oral Pathol .  57(2) :168-176. 
Stanley  HR, Diehl DL.  (1965) .  "Ameloblastoma Potenti al of Follicular Cysts ."  Oral Surg Oral 
Med Oral Pathol .  20:260-268. 
Sweeney  RT, McClary AC, Myers BR,  et al.  (2014) .  “Identification of recurrent SMO and BRAF 
mutations in ameloblastomas .”  Nat Genet .  46(7) :722-725. 
Tsai CY, Wei FC, Chang YL,  et al.  (2006) .  "Vastus lateralis muscle flap used for reconstruction 
of the maxilla after radical resection of recurrent ameloblastoma." Chang Gung Med J 
29(3) :331-335. 
Ueno S , Mushimoto K, Shirasu R al.  (1989) .  "Prognostic evaluation of ameloblastoma based on  
histologic and radiographic typing." J Oral Maxillofac Surg 47(1) :11-15. 
Urken ML, et al.  (1991) .  “Functional evaluation following microvascular oromandibular 
reconstruction of the oral cancer patient :  a comparative study of reconstructed and 
nonrecons tructed patients. ”  Laryngoscope .  101(9) :935-950. 
Urken ML, Buchbinder D, Costantino PD, et al.  (1998).  “ Oromandibular reconstruction using 
microvascular composite flaps :  report of 210 cases. ”  Arch Otolaryngol Head Neck Surg .  
124:46 -55.  
Vayvada H , Mola F, Menderes A,  et al.  (2006) .  “Surgical management of ameloblastoma in the 
mandible :  Segmental mandibulectomy and immediate reconstruction with free fibula or deep 
circumflex iliac artery flap (evaluation of the long -term esthetic and functional res ults). ”  J Oral 
Maxillofac Surg . 64(10) :1532 -1539 .  
Wedl C .  (1870) .  Pathologie der Zähne :  mit besonderer Rücksicht auf Anatomie und Physiologie .  
Felix .   
Wenig  BM.  (2008) .  Atlas of head and neck pathology .  Elsevier Health Sciences .   
Williams, CB, et al.  (2015) .  “A metastatic colon adenocarcinoma harboring BRAF -V600E has a 
durable major response to dabrafenib/trametinib and chemotherapy. ”  Onco Targets .  Ther 
8:3561 -3564.  
Williams TP .  (1993) .  “Management of ameloblastoma :  a changing perspective. ”  J Oral 
Maxillofac Surg .  51(10) :1064 -1070 .  
Wu PC, Chan KW. (1985) .  “A survey of tumours of the jawbones in Hong Kong Chinese :  
1963 -1982. ”  Br J Oral Maxillofac Surg .  23(2) :92-102. 
Zwahlen  RA, Gratz KW. (2002) .  "Maxillary ameloblastomas :  a review o f the literature and of a 
15-year database."   J Craniomaxillofac Surg .  30(5) :273-279. 
IRB-32275  57 of 59 21 August  2018;  Amendment  8 Appendix  A:  Medication guide  / Patient Information  for patients : 
Dabrafenib capsules  
The current Medication Guide for Tafinlar  (dabrafenib) dated November  2015 is attac hed to the 
eProtocol IRB -32275 application.  
Trametinib Tablets  
The current Patient Information for  Mekinist  (trametinib) is pr ovided in the package insert dated 
November  2015, attached to the eProtocol IRB -32275 application.  
 
Appendix  B:  Stanford  Cance r Institute Standard Operating Procedures  
Standard Operating Procedures (SOPs) for the Stanford Cancer Institute  (SCI) pertaining to risks 
to subjects and safety reporting are available on the SCI Cancer Clinical Trials Office website 
(http://med.stanford.edu/ccto/services/regulatory.html ).  
 
IRB-32275  58 of 59 21 August  2018;  Amendment  8 Appendix  C:  ECOG performance status  
 
 
 
IRB-32275  59 of 59 21 August  2018;  Amendment  8 Appendix  D:  Cockcroft -Gault formula:  
CCr={((l 40 –age) x weight)/(72xSCr)}x 0.85 (if female)  
Appendix  E:  Ophthalmic exam source sheet  
Note to examiner :  Please assess particularly for visible retinal pathology.  
* Optical coherence tomography is highly recommended   For patients in whom retinal abnormalities are noted, 
color fundus photos, and fluorescein angiog raphy if clinically indicated, are recommended.   
OPHTHALMIC EXAMINATION  Subject name/ MRN:  
1. Date of Examination:  _ _/_ _ _ /_ _ _ _  
   dd  /   mmm   /    yyyy  
VISUAL ACUITY  
Enter corrected visual acuity  OD: OS: 
TONOMETRY  
Enter IOP (mmHg)  OD: OS: 
INDIRECT FUNDOSCOPY  
Indirect Exam: Indicate 
normal or specify abnormalities  OD: OS: 
CONFRONTATION VISUAL FIELD EXAM OR AUTOMATED PERIMETRY 
(eg, Humphrey 24 -2 or 30 -2 or equivalent if using a non -Humphrey instrument)  
Indicate normal or specify any 
abnorm alities  OD: OS: 
OPTICAL COHERENCE TOMOGRAPHY (strongly recommended)  
Indicate normal or specify any 
abnormalities  OD: OS: 
COLOR FUNDUS PHOTOS (recommended if retinal abnormalities are noted)*  
Indicate normal or specify any 
abnormalities  OD: OS: 
FLORESC EIN ANGIOGRAPHY (suggested if retinal abnormalities are noted and 
test clinically indicated)*  
Indicate normal or specify any 
abnormalities  OD: OS: 
Were any of the following noted on ocular history or exam?  Yes No 
 History of CSR?    
 Evidence of new optic  disc cupping?    
 Evidence of new visual field defects?    
EXCLUSION CRITERIA  Yes No 
 History of RVO?  
o If yes, patient is not eligible for the study.    
Signature of Examiner: _____________________________   
Printed Name: _________________________      Date : ______________  